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Abstract 
 
Cognitive dysfunction is widely considered to be a core feature of schizophrenia, yet 
subpopulations that are cognitively “normal” have been repeatedly identified. There is no 
agreed upon definition of cognitive normality, with prevalence rates ranging from 0% to 
55%, and the clinical and functional implications are unclear. Interpretation of cognitive 
normality is further complicated by the possibility that normal-range patients have 
declined relative to premorbid ability. The purpose of this dissertation was to provide a 
deeper understanding of cognitive normality and its clinical and functional implications.  
Study 1 assessed the prevalence and clinical and functional validity of two definitions of 
cognitive normality: a narrow (i.e., IQ) and a broad (i.e., MCCB) definition. Participants 
included 99 patients with schizophrenia or schizoaffective disorder and 80 healthy 
controls. Prevalence rates of cognitive normality ranged from 14% to 48%. Regardless of 
the criterion applied, cognitively normal patients were functionally disadvantaged relative 
to cognitively normal controls. They demonstrated no advantage in functionality or 
clinical symptom severity relative to cognitively impaired patients. Study 2 evaluated a 
cognitive decrement algorithm (Keefe, Eesley, & Poe, 2005) and its clinical and 
functional validity among 156 patients and 74 controls. Patients were classified as having 
average range cognition with a decrement (37.1%), average-range without a decrement 
(9.3%), and above-average range without a decrement (12.1%). The combination of 
above average-range cognition and lack of a cognitive decrement conferred a functional 
advantage among patients, but they remained functionally disadvantaged relative to 
controls. Study 3 assessed the utility of the functionally relevant Breakfast Task (Craik & 
Bialystok, 2006) in predicting disability relative to standard measures of cognition and 
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symptom severity among 30 patients and 37 controls. Breakfast Task performance 
increased the ability to predict disability beyond that provided by cognitive and symptom 
measures. Results suggest that the prevalence of cognitive normality (9.3% to 48%) is a 
byproduct of the definition used. There was insufficient evidence supporting the 
functional or clinical validity of any of the definitions of cognitive normality, suggesting 
that the role of cognition in functioning has been largely over-emphasized in the 
literature. Ecologically valid tools, however, may hold promise for disability assessment.    
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Introduction 
Schizophrenia and Cognitive Functioning 
Schizophrenia is considered the most severe mental disorder, striking in late 
adolescence or early adulthood, with only 13.5% of patients eventually meeting clinical 
and social recovery criteria (Jääskeläinen et al., 2013). Both the prevalence rate of 1% 
(which is consistent around the globe) and the burden of disease remain substantial, and 
according to the World Health Organization, it is among the top disabling conditions 
worldwide for young adults (Charlson et al., 2018; Murray & Lopez, 1997a, 1997b).  
The concept and study of schizophrenia first emerged over a century ago, when 
Emil Kraepelin provided detailed accounts of what he formally termed dementia praecox; 
“psychic” symptoms (e.g., hallucinations) and “bodily” symptoms that were distinct from 
mood disorders (Kraepelin, 1896, 1919). The so-called “psychic” symptoms remain a 
core feature of schizophrenia today, a disorder which received its current name by 
Bleuler in 1950 (Bleuler, 1950) following his argument that the term “dementia” was 
inaccurate. Bleuler maintained that impaired thinking was the fundamental disturbance of 
schizophrenia. In fact, positive symptoms (i.e., hallucinations, delusions, and behavioral 
and speech abnormalities) were considered by Bleuler to be accessory symptoms, 
secondary to the more fundamental symptoms that were cognitive in nature. Nonetheless, 
for many years, there remained a consensus that cognitive functions were intact among 
patients with schizophrenia. When cognitive dysfunction was observed in a patient, it was 
typically attributed to effects of either medication or hospitalization (Torrey, Bowler, 
Taylor, & Gottesman, 1994).  
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It was not until the 1960s that cognitive dysfunction in schizophrenia gained 
wider attention. At that time, Watson’s study assessing neuropsychological function in 
people with schizophrenia and people with “chronic brain syndrome” revealed that these 
two patient groups were neuropsychologically indistinguishable (Watson, Thomas, 
Anderson, & Felling, 1968). Over the next couple of decades, studies demonstrating 
cognitive dysfunction were replicated by several researchers, and it was firmly concluded 
in the 1980s that “approximately three-quarters of our rigorously defined schizophrenia 
subjects showed marked to severe cognitive impairment” (Taylor & Abrams, 1984).  
Decades of research have since demonstrated that patients with schizophrenia 
exhibit impairment in various cognitive domains including sustained attention, verbal 
declarative memory, spatial working memory, executive functions, and general cognitive 
ability (Elvevag & Goldberg, 2000; Heinrichs & Zakzanis, 1998; Reichenberg & Harvey, 
2007). Cognitive dysfunction is now widely considered to be a core feature of 
schizophrenia, meaning it is thought to reflect underlying processes that would be present 
in anyone with the disorder, as opposed to secondary consequences of symptoms or 
treatment (Kremen, Seidman, Faraone, Toomey, & Tsuang, 2000). Cognitive function is 
also regarded as a core feature because it is present prior to and at the onset of the illness 
(Kremen et al., 1998; Meier et al., 2014), it is found in non-psychotic biological relatives 
(Keefe et al., 1994; Toulopoulou et al., 2007), and it tends to be treatment-resistant 
compared to other illness characteristics (Keefe & Harvey, 2012). Cognitive impairment 
is rarely correlated with psychotic symptoms (for a review see Keefe & Harvey, 2012) 
and even when symptoms are relatively remitted, cognitive dysfunction persists (Gold & 
Harvey, 1993).  
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Importantly, a meta-analysis identified that the generalized cognitive impairment 
observed in schizophrenia has remained evident over nearly three decades of research, 
despite developments and changes in assessment tools and diagnostic criteria, and despite 
linguistic and cultural differences among the regions in which the studies have been 
conduced (Schaefer, Giangrande, Weinberger, & Dickinson, 2013). Cognitive deficits 
continue, therefore, to be considered the primary expression of schizophrenia (Heinrichs, 
2005) with some researchers urging the field to shift diagnostic and treatment efforts on 
cognitive dysfunction, rather than continue the prevailing emphasis on psychotic 
symptoms (Kahn & Keefe, 2013). 
Cognitive Normality in Schizophrenia 
In 1997, Palmer et al. (Palmer, Heaton, Paulsen, Kuck, & Braff, 1997) posed a 
question that seemingly contradicted the extensive body of literature supporting impaired 
cognition as a core feature of schizophrenia.  The question, posed in their article of the 
same name, was: “Is it possible to be schizophrenic yet neuropsychological normal?” (p. 
437). They found that 11.1% of the patients with schizophrenia demonstrated no 
impairments on any measure within a comprehensive neuropsychological battery that 
assessed verbal ability, psychomotor skill, abstraction and cognitive flexibility, attention, 
learning and retention, motor skills, and sensory ability. This finding, according to the 
authors, confirmed the existence of patients with normal neuropsychological abilities. 
This claim that it was possible to be schizophrenic yet neuropsychologically normal was 
supported by several prior studies that reported a subset of schizophrenia patients were 
neuropsychologically unimpaired based on performance on the Luria-Nebraksa 
Neuropsychological Battery (Bryson, Silverstein, Nathan, & Stephen, 1993; Golden et 
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al., 1982; Silverstein, Mcdonald, & Meltzer, 1985; Silverstein & Zerwic, 1985),	
comprehensive neuropsychological batteries (Heinrichs & Awad, 1993), and executive 
function tasks (Goldstein, 1990). A substantial body of literature has since emerged 
reporting the existence of subgroups with preserved cognitive ability, yet with notable 
inconsistencies in the reported prevalence rates of normality.  
To date, there have been different approaches used to define the construct of 
cognitive normality, applied individually or jointly, depending on the study. These 
approaches include relying on population norms, relying on control group performance as 
a comparison, directly indexing one’s current performance against their premorbid or 
baseline cognitive functions, and using expert ratings of neuropsychological impairment. 
Within the literature, there are numerous different criteria used to classify normality, or 
impairment, based on an approach that relies on normative data from healthy control 
populations. For instance, the Global Deficit Score (GDS) approach for classifying 
neuropsychological impairment (Heaton et al., 1994) converts T-scores to deficit scores, 
with T-scores greater than 40 falling within normal limits and as such indicate no 
impairment. The magnitude of the deficit score increases as the T-score decreases (e.g., 
T-scores = 39 – 35 are assigned a deficit score of 1, whereas T-scores < 20 are assigned a 
deficit score of 4). Deficit scores across all administered tests are then averaged to 
generate a GDS. Applying this criterion, Reichenberg and colleagues classified 81.9% of 
patients with schizophrenia as impaired (and presumably 18.1% were normal) 
(Reichenberg et al., 2008) using a battery of neuropsychological tests assessing eight 
cognitive domains (i.e., general verbal ability, verbal declarative memory, visual 
declarative memory, abstraction-executive function, attention and processing speed, 
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simple motor skills, visual processing, and language ability).  
Further, Leung et al. (2008) found in their study of older outpatients with 
schizophrenia that 18.5% of patients were classified as neuropsychologically normal 
according to GDS classification criteria. Chiang et al. (2016) also applied GDS criteria to 
a sample of patients of Han Chinese ethnicity with schizophrenia and reported that 41% 
of patients performed within the cognitively normal range. The GDS criteria have also 
been used to classify cognitive normality in schizophrenia in conjunction with an 
additional criterion that no more than 1 out of 6 cognitive dimensions are 1 SD below 
healthy controls’ mean z-scores (González-Blanch et al., 2010). These criteria were 
applied to a sample of first-episode patients with schizophrenia who were administered a 
test battery consisting of measures of verbal learning and memory, verbal 
comprehension, speed of processing and executive functioning, visual memory, motor 
dexterity, and sustained attention/vigilance. Results of this study indicated that 23% of 
patients were identified as neuropsychologically within normal limits.  
Another published classification system is based on the accepted definitions of 
clinically significant cognitive impairment (CSCI), used by Palmer et al. (1997) in their 
seminal study on cognitive normality in schizophrenia. Classification using the CSCI 
definitions considered impairment to be a performance of 1 SD or more below the 
general population mean based on corrected scores in at least two out of eight specific 
ability areas that were assessed (i.e., verbal ability, psychomotor skill, abstraction and 
cognitive flexibility, attention, learning, retention, motor skills, and sensory ability). This 
classification yielded 11% of patients who were classified as cognitively normal across 
all ability areas (Palmer et al., 1997). Similarly, Reichenberg et al., (2008) found that 
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16% of patients with schizophrenia were cognitively normal based on the CSCI criteria. 
In addition to the GDS and CSCI classification systems, the Individual Rating 
Procedure (IRP) has been used to classify cognitive normality in patients with 
schizophrenia (Kremen et al., 2000). Using this method, Kremen et al. (2000) converted 
scores on neuropsychological tests assessing eight cognitive abilities (i.e., general verbal 
ability, general visual-spatial ability, verbal declarative memory, abstraction-executive 
function, executive-motor function, perceptual-motor speed, mental-control encoding, 
and sustained-attention vigilance) to z-scores. The mean of the z-scores of the individual 
measures comprising the ability area was calculated to represent performance in each 
ability area. A profile was considered abnormal if two or more ability areas were more 
than two SDs below the normative mean, or if one ability area was more than three SDs 
below the mean. Using the IRP, Kremen et al. (2000) found that 23% of patients with 
schizophrenia had a profile within normal limits (WNL). Applying the same IRP, 
Reichenberg et al. (2008) found that 45% of patients with schizophrenia were unimpaired 
(and 54% were impaired). When all three criteria (i.e., GDS, CSCI, IPR) were combined 
to create an omnibus impairment criteria, 15% of the patients with schizophrenia were 
classified as cognitively normal across all three criteria, and 53% were classified as 
impaired (Reichenberg et al., 2008).  
Further, the Average Impairment Rating (AIR) criterion pertaining to the 
Halstead-Reitan Neuropsychological Battery (HRB) (Reitan & Wolfson, 1993) was used 
to classify performance on the major tests of the HRB (Allen, Goldstein, & Warnick, 
2003). Results indicated that based on the AIR classification criteria, 19.5% of patients 
with schizophrenia were classified as neuropsychologically normal.  
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Other classification systems based on comprehensive neuropsychological 
batteries have been used to identify neuropsychologically normal patients with 
schizophrenia. For instance, Holthausen et al., (2002) classified cognitive impairment in 
schizophrenia as one z-score of 2 or more SDs below the normative mean within an 
assessed ability area (i.e., perceptual sensitivity, attention selectivity, perceptual and 
psychomotor speed, memory-verbal encoding, memory-verbal consolidation, memory-
verbal retrieval, memory-visual, verbal fluency, and visuoconstruction). Using this 
criterion, the authors found that 19% of patients were cognitively unimpaired. As well, 
Heinrichs et al. (2015) defined cognitive normality as a MATRICS Consensus Cognitive 
Battery (MCCB) Composite T-score between 40 and 60. Using this MCCB-based 
definition of normality, 18% of patients were classified as cognitively normal.  
The aforementioned studies largely defined cognitive normality based on a 
composite or summary score pertaining to a comprehensive neuropsychological battery 
assessing multiple cognitive domains. Ammari et al. (2010) assessed more specific ability 
measures as an indicator of cognitive normality, in particular verbal memory (CVLT-II), 
in addition to verbal (i.e., Vocabulary) and non-verbal (i.e., Matrix Reasoning) abilities 
on the WAIS-III (Wechsler, 1997a). Specifically, cognitive normality was defined as 
CVLT-II trials 1-5 T scores > 43 and < 60, and WAIS-III Scaled Scores > 8 and < 13. 
These criteria resulted in the identification of 15% of patients who were cognitively 
normal.  
Among the studies that have examined cognitive normality, one which is 
frequently cited as reporting the highest prevalence of normality was conducted by 
Torrey, Bowler, Taylor, & Gottesman (1994). In their study of cognitive function among 
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identical twins with and without schizophrenia, they found that 13 out of 27 (48%) 
affected twins were classified as less impaired or completely unimpaired, whereas the 
remaining 14 affected twins were moderately or severely neuropsychologically impaired. 
Critically, with only three affected twins showing severe cognitive impairments, some 
sources (Harvey & Keefe, 2009) seem to interpret the results of this study to suggest that 
11% of patients demonstrated cognitive impairment, and consequently 89% demonstrated 
cognitive normality. Therefore, even within one study (e.g., Torrey et al., 1994), the 
prevalence rates of cognitive normality may vary depending on the interpretation 
“normality” and/ or “impairment”.  
Perhaps the most definitively stated position on cognitive normality in 
schizophrenia comes from Wilk et al. (2005). The authors appear to respond to Palmer’s 
seminal 1997 article (“Is it possible to be schizophrenic yet neuropsychological 
normal?”), by stating, “No, it is not possible to be schizophrenic and 
neuropsychologically normal” (p. 778) in their article of the same name. To assess 
whether normal-range performance does in fact preclude neuropsychological abnormality 
in patients with schizophrenia, the authors closely matched individual patients with 
schizophrenia and healthy controls in terms of age, education, and WAIS-III Full-Scale 
IQ (FSIQ) (Wechsler, 1997a). Results indicated that despite being closely matched on 
FSIQ, patients with schizophrenia demonstrated performance deficits in the processing 
speed and working memory indices on the WAIS-III, and in the general memory and 
immediate memory indices on the Wechsler Memory Scale (3rd ed.; Wechsler, 1997b). 
Therefore, despite normal range FSIQ scores, patients with schizophrenia still 
demonstrated neuropsychological abnormality upon closer inspection of domains such as 
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processing speed and memory. The authors therefore concluded that, “No, it is not 
possible to be schizophrenic yet neuropsychological normal” (p. 778).  
Our understanding of cognitive normality in patients with schizophrenia considers 
that the issues are both complicated and nuanced, and that this area remains controversial, 
as cognitive dysfunction is widely considered to be a core feature of the illness. As well, 
the prevalence of cognitive normality varies widely, from 55% (Bryson et al., 1993) to 
0% (Wilk et al., 2005), with the majority of prevalence rates falling within the 15% to 
25% range. A critical issue in the field is that there is no agreed upon definition of 
cognitive normality, as has been demonstrated in the review of the aforementioned 
studies. As a result, there are various criteria in existing literature that have been used to 
classify patients as cognitively normal. This lack of consensus of cognitive normality 
definitions likely contributes to the inconsistencies in the prevalence of cognitive 
normality cited in the literature, and is therefore an obstacle to research efforts aiming to 
investigate the existence, nature and significance of this subgroup. Further, multiple 
definitions of cognitive normality are rarely applied within one research study, rendering 
the prevalence rates of cognitive normality more questionable given the likely participant 
heterogeneity between various research studies with their differing inclusion criteria (e.g., 
inpatients, outpatients, duration of illness, medication status, comorbidity). There is a 
need to critically examine the divergent definitions in order to resolve the methodological 
discrepancies that seem to be confounding the field, and to arrive at a more accurate 
estimate of the prevalence of cognitive normality.  
Cognitive Decrement in Schizophrenia 
Our understanding of cognitive normality and its implications is further 
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complicated by the possibility that patients who exhibit cognitive performance that 
overlaps with healthy control performance at the time of testing may have actually fallen 
below expectations based on premorbid estimates (i.e., premorbid abilities are assumed, 
rather than directly observed), reflecting a cognitive function decrement. Therefore, 
despite performing within the range of cognitive normality, these patients may be 
performing more poorly than would be expected if they had not developed schizophrenia. 
In addition to relying on population norms to define the construct of cognitive normality, 
a substantial body of literature has focused on directly indexing current performance 
against premorbid or baseline cognitive functions as an approach to assessing cognitive 
normality.  
For instance, in their assessment of monozygotic twins discordant for 
schizophrenia, Goldberg et al. (1990) found that the majority of affected twins performed 
worse than their unaffected twins on a series of neuropsychological assessments, a 
pattern which remained even when affected twins’ performance fell within normal limits. 
This was early evidence that patients who are cognitively normal may nonetheless have 
deficits compared to what their performance level would have been if they had not 
developed schizophrenia. The same pattern of findings pertaining to a potential cognitive 
decrement has been shown to apply to intellectually superior patients with schizophrenia 
as well, when intellectually superior patients were compared to IQ-matched healthy 
controls (Vaskinn et al., 2014).  
 As direct assessments of premorbid level of cognitive functioning are rarely 
available, different approaches are adopted to estimate if there has been a cognitive 
decline. For instance, objective records, such as school or employment records, or more 
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subjective indicators such as self-report data can be collected, but there are limitations 
inherent in these approaches, such as availability and accuracy (Gladsjo, Heaton, Palmer, 
Taylor, & Jeste, 1999). A preferred method for estimating premorbid cognitive 
functioning is the assessment of current abilities - for example oral reading - that are 
thought to be resistant to brain disorders (Nelson & O’Connell, 1978; Nelson, 1982). 
Indeed, tests of word reading have been shown to provide the most precise and reliable 
estimate of intellectual functioning, and their use in predicting premorbid IQ for a range 
of neurological conditions is well-supported (Bright, Jaldow, & Kopelman, 2002; Bright 
& van der Linde, 2018). 
 Performance on measures of oral reading has been used as an estimate of 
premorbid intellectual functioning to assess for cognitive function decline in patients with 
schizophrenia. Based on performance on an oral reading test, the Wide-Range 
Achievement Test – Revised Reading Subtest (WRAT-R; Jastak & Wilkinson, 1984), as 
an indicator of premorbid ability, patients with schizophrenia performing within normal 
limits on a comprehensive battery of neuropsychological tests (according to IRP criteria) 
demonstrated higher estimated premorbid ability compared to controls matched on 
overall neuropsychological test performance (Kremen et al., 2000). This finding suggests 
a decline from premorbid functioning among patients performing in the normal range. 
However, the reported prevalence of patients with schizophrenia that do not demonstrate 
a cognitive decline based on oral reading indicators of premorbid estimates varies in the 
literature, ranging from 4.7% to 29% (Keefe et al., 2005; Potter & Nestor, 2010; 
Woodward & Heckers, 2015).  
 In addition to performance on tasks of oral reading, parental education has also 
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been examined as an estimate of premorbid intellectual potential (Kareken, Gur, & 
Saykin, 1995). Parental education has been proposed to be especially useful in 
schizophrenia due to its heritability with genes and environment, the 48% to 60% 
heritability of IQ (Bouchard & McGue, 2003), and since parental education may be 
unaffected by the patient’s level of motivation or disease onset that may impede their 
own educational achievement (Plomin, 1986; Resnick, 1992). Applying this premorbid 
estimate in the field of schizophrenia, Keefe et al. (2005) reported that only 3.8% of 
patients performed at or above cognitive levels predicted by maternal education. Keefe 
and colleagues also showed that when both reading scores and maternal education were 
combined to predict current cognitive performance, only 1.9% of patients performed at or 
above expectations.  Critically, while Keefe and colleagues label this discrepancy 
between current cognitive performance and premorbid estimates as a “decrement”, their 
data are not longitudinal in nature, and therefore the term decrement must be interpreted 
with caution, as a decrement has been assumed, rather than observed.  
Work by Keefe and colleagues (2005) suggested that cognitive functioning is 
lower in all patients when compared with their genetic and environmental intellectual 
potential (e.g., parental education and reading scores). Their work has yet to be 
replicated, and it remains unknown if patients who are “truly” cognitively normal (i.e., 
performing in the “normal” range cognitively without having experienced a decline based 
on premorbid levels) differ functionally or clinically from patients who perform in the 
normal-range but have experienced a decline.  
Cognitive Normality and Implications for Daily Functioning and Clinical Features  
In addition to the long-standing consensus that cognitive impairment is a core 
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feature of schizophrenia, it is widely understood that patients with schizophrenia 
demonstrate impairments in multiple domains of everyday functioning, such as 
educational achievement, employment, independent living skills, ability to fulfill social 
roles, and the ability to seek needed healthcare services. These impairments are in turn 
related to increased rates of poverty, major medical morbidity, and social isolation among 
this population (Harvey, Velligan, & Bellack, 2007). Despite advancements in treating 
the positive symptoms of the disorder, with up to 40% of patients experiencing clinical 
remission (Hert et al., 2007), functional impairment tends to persist (Harvey et al., 2012). 
Therefore, there is a strong need for an increased understanding of the determinants of 
and treatment for functional impairments.  
Cognitive impairment has long been regarded as a cause of impairment in 
functional capacity (i.e., daily living skills demonstrated by performance in ideal 
environments) and related outcomes, such as residential functioning, employment, quality 
of life, and medication adherence among patients with schizophrenia (Bowie, 
Reichenberg, Patterson, Heaton, & Harvey, 2006; Green, Kern, Braff, & Mintz, 2000; 
Keefe & Harvey, 2012; Kuo et al., 2018; Matza et al., 2006). A comprehensive meta-
analysis, however, has shown that cognition accounts for only 6% of functionality 
variance, with the addition of social cognition accounting for up to about 16% (Fett et al., 
2011). Further, cognitively normal patients fail to show any functional advantage in 
community adjustment relative to cognitively impaired patients (Alden, Cobia, Reilly, & 
Smith, 2015; Heinrichs et al., 2015; Heinrichs, Parlar, & Pinnock, 2017; Moore et al., 
2015; Muharib et al., 2014). Leung et al. (2008a) did find, however, that cognitively 
normal patients (based on the GDS classification) had better functional capacity relative 
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to cognitively impaired patients. Critically though, these cognitively normal patients were 
still disadvantaged relative to controls in terms of functional capacity and independence 
in residential status. As well, while behavioural interventions demonstrate success at 
improving cognition, these interventions do not demonstrate a strong ability to generalize 
to daily life functioning (Kidd et al., 2014; Lin, Tsai, & Lane, 2014). Given the various 
definitions of cognitive normality used in the literature, it is unclear if different 
classifications of cognitive normality (e.g., more or less stringent classifications) may 
have different associations with functioning.   
In addition to the association between cognition and functioning, many studies 
have investigated the association between cognition and symptom severity among 
patients with schizophrenia. The relation between symptom severity and cognitive 
functioning is less equivocal, with studies generally pointing towards a lack of 
association between the two (Ammari et al., 2010; Dibben, Rice, Laws, & McKenna, 
2009; Nieuwenstein, Aleman, & De Haan, 2001). There are, however, reports that 
negative symptoms, but not positive symptoms, are associated with poorer cognitive 
function among patients (Addington, Addington, & Maticka-Tyndale, 1991; de Gracia 
Dominguez, Viechtbauer, Simons, van Os, & Krabbendam, 2009; Harvey, Koren, 
Reichenberg, & Bowie, 2006). The extent to which different classifications of cognitive 
normality are related to symptom severity remains relatively understudied.    
Novel Approaches to Assessing Cognitive Function Underlying Daily Functioning 
and Disability   
Despite the common conception that cognition is considered a primary predictor 
of functioning, the meta-analytic finding that cognition (and social cognition) accounts 
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for only 6-16% of the variance in functional outcome (Fett et al., 2011) cannot be 
ignored. This finding suggests that either cognition does not play a substantial role in 
daily functioning and disability among schizophrenia, or that perhaps cognitive measures 
that incorporate more functionally relevant stimuli may have better utility than traditional 
neuropsychological assessments in accounting for variance in daily functioning. The 
latter interpretation is supported by Harvey et al. (2007), who posited that performance-
based measures of functional skills could provide a more valid estimate of functional 
impairment as compared to traditional neuropsychological assessment measures. Further, 
measures of executive function, a cognitive domain that supports the ability to carry out 
many instrumental activities of daily living, have been criticized for their poor 
generalizability to real-world behavior. For instance, poor performance on the widely 
used Wisconsin Card Sorting Task (Grant & Berg, 1948) is not necessarily related to 
poor executive behavior in everyday life, while good performance on this task can still be 
accompanied by dysexecutive problems in everyday life, a pattern that has been 
repeatedly demonstrated among patients with frontal lesions (Tanguay, Davidson, 
Guerrero Nuñez, & Ferland, 2014).  
An alternative approach to the use of standard cognitive measures in the 
prediction of real world functioning is to employ more real-world tasks that rely on 
multiple executive functions. These tasks are considered to be more ecologically valid in 
their relevance to carrying out a task in the real world. For instance, the Canadian 
Objective Assessment of Life Skills (COALS; (McDermid Vaz et al., 2012) is a 
performance-based measure designed to assess routine procedural knowledge and 
executive operations involved in functional outcome domains such as health and hygiene, 
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time management, transportation, crisis management, and domestic activates. Critically, 
performance on the COALS provided predictive validity of community independence 
above and beyond that provided by symptoms and intellectual ability among patients with 
schizophrenia (McDermid Vaz et al., 2012). However, scores on the University of 
California San Diego Performance Skills Assessment (UPSA), another measure of 
functional capacity, failed to significantly enhance the validity achieved with standard 
cognitive measures in predicting community functioning (Heinrichs, Ammari, Miles, & 
McDermid Vaz, 2010). These findings are in contrast with those pertaining to the 
COALS (McDermid Vaz et al., 2012). Therefore, the incremental validity of functional 
competence measures in predicting community functioning relative to standard cognitive 
measures is equivocal, and may relate at least partially to the specific measure utilized.  
A challenge inherent in the design and ecological validity of real-world tasks is 
the consideration of which day-to-day tasks draw heavily on cognitive domains such as 
executive functioning. Cooking has long been regarded as a solid example of a task that 
is highly reliant on frontal lobe/executive functions. This was first demonstrated by 
Wilder Penfield (Penfield & Evans, 1935) in a study documenting the effects following a 
frontal lobe resection he performed on his sister. Penfield and Evans (1935) made the 
following observation regarding Penfield’s sister:  
One day about fifteen months after operation she had planned to get a simple 
supper for one guest and four members of her own family. She had looked 
forward to it with pleasure and had the whole day for preparation. This was a 
thing she could have done with ease ten years before. When the appointed hour 
arrived she was in the kitchen, the food was all there, one or two things were on 
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the stove, but the salad was not ready, the meat had not been started and she was 
distressed and confused by her long continued effort alone. It seemed evident that 
she would never be able to get everything ready at once. (p. 131) 
 The etiology (frontal lobe resection) underlying the executive dysfunction in 
Penfield’s case study differs from the current study among patients with schizophrenia, 
yet the principle that cooking relies on executive functions remains the same.   
Craik and Bialystok (2006) developed The Breakfast Task, a computer game that 
provides a naturalistic measure of different aspects of executive functioning for cognitive 
rehabilitation purposes. This computerized game simulates cooking breakfast while 
setting a table, achieving a balance of the advantages of experimental control inherent to 
traditional tasks of executive function, with the varying demands of real-world situations 
that draw largely on executive functions.  To date, performance on this computerized task 
has been studied in patients with acquired brain injury (ABI) (Tanguay et al., 2014), and 
older adults (Craik & Bialystok, 2006; Rose et al., 2015). Relative to controls, patients 
with ABI perform worse on all measures of the Breakfast Task as compared to controls 
(Tanguay et al., 2014). Evidence suggests that the Breakfast Task provides measures of 
global and local planning abilities that are related to task switching, working memory, 
and prospective memory (Craik & Bialystok, 2006; Rose et al., 2015). Therefore, there is 
preliminary support for the use of the Breakfast Task in assessing real-world planning 
and monitoring, and also for its ability to distinguish healthy controls from those with an 
ABI.  This task has yet to be used among patients with schizophrenia and its utility in this 
population in terms of accounting for variance in community independence remains 
unclear.  Given the well-supported findings that real-world and cognitive (including 
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executive) functions are impaired in patients with schizophrenia, the Breakfast Task may 
strike a balance between the two areas of functioning in such a way that offers a strong 
predictive validity of disability in this population.  
Current Program of Research  
The current program of research consists of three studies that aimed to further our 
understanding of cognitive normality in schizophrenia by: i) examining the prevalence 
and clinical and functional validity of broad and narrow definitions of cognitive 
normality, ii) evaluating a cognitive decrement algorithm (Keefe et al., 2005) and its 
clinical and functional validity, and iii) examining the utility of a real-world functional 
task in predicting disability.   
With the existing literature, we are only able to compare prevalence rates across 
different studies with heterogeneous participant samples recruited using different 
inclusion and exclusion criteria. These heterogeneous participant groups may have 
inherent confounding variables that impact the prevalence rates of cognitive normality. 
The purpose of Study 1 was to assess and report the prevalence of different definitions of 
cognitive normality criteria (i.e., “Narrow” and “Broad”) among the same study sample. 
Specifically, the criteria for the Narrow classification of normality consisted of an IQ 
summary index (e.g., Ammari et al., 2010; Kremen, Seidman, Faraone, & Tsuang, 2001), 
and the criteria for the Broad classification consisted of the MATRICS Consensus 
Cognitive Battery (MCCB: Nuechterlein et al., 2008) composite scores, for a more broad-
based measure. This approach to cognitive normality classification therefore relied on 
population norms. To understand the clinical and functional implications of the different 
definitions of cognitive normality, patients who met criteria for different definitions of 
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cognitive normality were compared to cognitively normal healthy controls as well as 
cognitively impaired patients on measures of community independence and symptom 
severity. 
The purpose of Study 2 was to expand on work done by Keefe et al. (2005) by 
evaluating the reproducibility of their results pertaining to their cognitive function 
decrement algorithm. In their approach, Keefe et al. (2005) directly indexed participants’ 
current performance against their premorbid or baseline cognitive functions, specifically 
using parental education and reading scores as estimates. Following an evaluation of 
Keefe’s cognitive decrement algorithm, Study 2 also examined the clinical and functional 
implications of being a “truly” cognitively normal patient. That is, analyses focused on 
the subset of patients who met criteria for cognitive normality based on a composite z-
score, and who have not experienced a cognitive decrement based on genetic and 
environmental expectations (parental education and reading scores). This study aimed to 
further our knowledge of cognitive normality by determining the proportion of patients 
who, despite meeting cognitive normality criteria, have actually experienced a decline in 
their cognitive function.  
In addition to assessing the clinical and functional implications of different 
definitions of cognitive normality and cognitive function decrement, the current 
investigations included an assessment of the incremental validity of a naturalistic 
measure of varied aspects of executive functioning in predicting disability relative to 
standard measures of cognition and symptom severity (Study 3). The naturalistic measure 
used in Study 3 was The Breakfast Task, a computerized task that may hold more 
functional relevance as compared to standard measures of cognition.  
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Study 1 
As discussed, the purpose of Study 1 was to assess and report the prevalence of 
and functional and clinical implications of different definitions of cognitive normality 
(i.e., “Narrow” and “Broad”) among patients with schizophrenia.  
Hypotheses  
It was predicted that prevalence rates of cognitive normality among both patients 
and controls would vary based on the two different definitions of normality. These 
definitions included: i) Narrow-Normal Range (NaNR); and ii) Broad-Normal Range 
(BrNR). It was also expected that prevalence rates would vary as a result of the 
stringency of the definition, with the following prevalence rates: NaNR > BrNR. As well, 
regardless of the definition of cognitive normality (NaNR and BrNR), it was 
hypothesized that patients who are cognitively normal would exhibit a functional, but not 
clinical advantage (i.e., reduced symptom severity) relative to patients who performed 
below the range of cognitive normality.  
Methods 
Participants 
Participants included 99 patients (76 males, 23 females) who met diagnostic 
criteria for schizophrenia (n = 77) or schizoaffective disorder (n = 22) and 80 non-
psychiatric controls (54 males, 26 females). Diagnosis was confirmed by the Structured 
Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition 
(First, Spitzer, Gibbon, & Williams, 1996). Patients were included if they met the 
following criteria: 1) age 18-65 years; 2) no history of developmental disability or serious 
neurological or endocrine disorder; 3) no concurrent DSM-IV diagnoses of substance 
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abuse or dependence; and 4) willingness and ability to sign informed consent. Patients 
were recruited from outpatient settings in south central Ontario, and controls were 
recruited by posting for paid research participation in community newspapers and online 
advertisements. Controls were excluded for medical, neurological, and psychiatric illness, 
and for developmental disability based on responses provided on a screening 
questionnaire. Control participants were group matched to patients on age, gender, 
language background and parental socioeconomic background 
Measures 
Current clinical symptom severity was evaluated with the Positive and Negative 
Syndrome Scale (PANSS; Opler et al., 1999). Neurocognitive assessment in both patients 
and non-psychiatric controls included the MATRICS Consensus Cognitive Battery 
(MCCB; Nuechterlein et al., 2008), which is comprised of measures of working memory, 
attention, verbal memory, visual learning, processing speed, reasoning and problem-
solving, and social cognition. The MCCB yields a composite score representing an 
overall measure of cognitive performance. The Wechsler Abbreviated Scale of 
Intelligence (WASI; Wechsler, 1999) Vocabulary and Matrix Reasoning subtests were 
administered to obtain an estimate of general intellectual ability (i.e., WASI Two-Subtest 
IQ).  
Community independence was measured with the overall Global rating from the 
Multidimensional Scale of Independent Functioning (MSIF; Jaeger, Berns, 
Multidimensional, & Functioning, 2003) in both patients and healthy controls. The MSIF 
comprises a structured interview and self-report measure. The Global Rating reflects the 
level of functioning across residential, work, and educational settings while considering 
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role position, level of performance, and degree of assistance required. Scores range from 
one to seven, with higher scores indicating poorer function. That is, a score of one 
indicates essentially normal functioning with little-to-no support, whereas a rating of 
seven indicates total disability. The interclass correlation coefficients for the overall 
global rating has been shown to be 0.90, and there is moderate internal consistency 
among the subcomponents of the MSIF (Jaeger et al., 2003).  
Analyses 
Group assignment procedure 
Group assignment to the Narrow Normal-Range (NaNR) group was based on the 
following criteria: WASI Two-Subtest IQ score equal to or between 90 and 109, to reflect 
Average range performance according to Wechsler qualitative descriptors. Based on this 
narrow measure of cognition, cognitively below-normal range was defined as a WASI 
Two-Subtest IQ score less than 90.  This classification yielded 47 NaNR patients (48%), 
18 above NaNR patients (18%), and 34 patients falling below the NaNR (34%) when 
applying these criteria to the entire sample of patients (n = 99). This classification yielded 
28 NaNR controls (35%), 41 above NaNR controls (51%), and 11 below NaNR Controls 
(14%) when applying these criteria to the entire sample of controls (n = 80).    
Group assignment to the Broad Normal-Range (BrNR) group was based on the 
following criteria: MCCB composite T score equal to or between 40 and 60, consistent 
with previous studies employing this criterion with the MCCB (Heinrichs et al., 2015; 
Muharib et al., 2014). If participants met criteria for both NaNR and BrNR, they were 
classified as BrNR for the purpose of statistical analysis to ensure that no participants 
were included in both cognitive subtype groups for group comparisons. Based on this 
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broad measure, cognitively below-normal range was defined as an MCCB composite T 
score ranging from 20 to 39. This classification yielded 13 BrNR patients (14%), 0 above 
BrNR patients (0%), and 82 patients falling below the BrNR (86%) when applying these 
criteria to the entire sample of patients (n = 95). The classification yielded 52 BrNR 
controls (65%), one above BrNR control (1%), and 26 below BrNR Controls (33%) when 
applying these criteria to the entire sample of controls (n = 79).    
Given the low prevalence (14%) of BrNR patients, and to ensure demographic 
similarity with comparison subgroups, these patients’ age range and sex proportion were 
used as criteria in assigning controls to a normal range (NR) ability group, patients to the 
NaNR ability group, and patients to the below-normal range group for statistical analyses. 
Hence, inclusion criteria for the normal range control group were: 1) age 20 – 46, 2) sex 
ratio 65-85% male; and 3) MCCB composite T score between 40 and 60 or IQ between 
90 – 109. There were only three controls within the NaNR group who met age-range 
criteria, as the majority of controls also met criteria for the BrNR group. Therefore, 
NaNR and BrNR controls were combined to form one normal-range control group, rather 
than separating controls into their NaNR and BrNR groups for analyses. A total of n = 25 
controls met these criteria and were assigned to a normal-range group. For patients, 
inclusion criteria for the NaNR group included: 1) age 20 – 46; 2) sex ratio 65-85% 
males; and 3) WASI Two-Subtest IQ score equal to or between 90 and 109. These 
requirements were met by n = 25 patients, who were therefore assigned to the NaNR 
category. The cognitively below-normal range (BNR) patient group was defined as an 
MCCB composite score less than or equal to 39 and an IQ score less than or equal to 89. 
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Applying the age, sex, IQ, and MCCB criterion to the pool of patients yielded n = 13 
patients falling into the BNR group (see Table 1).  
See Appendix A for additional analyses pertaining to group assignment to the 
BrNR group based on MCCB composite T scores equal to or between 43 and 57, with 
those T score parameters set in order to achieve psychometric equivalence with the WASI 
IQ score criterion for average-range performance (based on Wechsler Classification). 
Results 
Demographic characteristics of the NaNR, BrNR patient groups, the BNR 
patients, and the NR comparison controls are presented in Table 1. Patient and control 
subgroups did not differ significantly in terms of age, sex distribution, or proportion for 
whom English was their first language. Groups did differ in terms of years of education; 
the NR controls reported significantly higher levels of education compared to the three 
patient groups (ps < .05), however patient groups did not differ from one another in terms 
of years of education.  
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Table 1 
Descriptive and Criterion Data for Below Normal-Range (BNR) Patients, Narrow 
Normal-Range (NaNR) Patients, Broad Normal-Range (BrNR) Patients, and Normal 
Range (NR) Controls 
 
Variables BNR 
Patients 
(n = 13) 
NaNR 
Patients  
(n = 25) 
BrNR 
Patients  
(n = 13) 
NR 
Controls  
(n = 25) 
Statistic 
Age, yrs  
(M, SD) 
 
35.31 
(6.46) 
34.96 
(6.54) 
30.31 
(7.29) 
30.32 
(8.49) 
F(3,72) = 2.66 
Sex  
(males %) 
 
85 76 77 68 FET = 1.26 
Years 
Education  
(M, SD) 
 
11.69 
(1.25) 
13.08 
(2.64) 
13.92 
(1.98) 
16.44 
(2.29) 
F(3,72) = 15.94 ** 
First 
Language 
English (%) 
 
83 84 69 58 FET = 4.66 
MCCB 
Composite 
T  
(M, SD) 
 
20.62 
(8.64) 
30.04 
(7.17) 
48.08 
(5.01) 
46.28 
(6.81) 
F(3,71) = 57.0 ** 
WASI 2-
Subtest IQ  
(M, SD) 
78.22 
(7.42) 
99.44 
(5.28) 
114.00 
(11.39) 
106.64 
(18.05) 
F(3,72) = 21.94 ** 
Note: FET = Fisher’s Exact Test; M = mean; MCCB = MATRICS Consensus Cognitive 
Battery; SD = standard deviation; WASI = Wechsler Abbreviated Intelligence Scale.  
** p < .001 
 
Functional implications of NaNR and BrNR subtypes  
Assumptions for ANOVA were assessed. Based on the interquartile range and 
boxplot, there were no outliers among MSIF scores. Results of the Shapiro-Wilk test (p = 
.01) indicated that the distribution of the residuals of MSIF scores was not normal, and 
residuals remained non-normally distributed following log transformation. Therefore, the 
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non-parametric Kruskal-Wallis test was performed to compare the effect of group (i.e., 
BNR patients, NaNR patients, BrNR patients, and NR Controls) on community outcome 
(i.e., MSIF global scores), with post-hoc Mann-Whitney tests conducted with Bonferroni 
correction.  
MSIF scores were significantly affected by participant group (H(3) = 36.80, p < 
.001). Mann-Whitney tests were used to follow up on this finding based on the following 
comparisons: i) BNR patients vs. NaNR patients; ii) BNR patients vs. BrNR patients; iii) 
NaNR patients vs. NR controls; and iv) BrNR patients vs. NR controls, with only these 
select Mann-Whitney tests chosen to reduce the Type I error rate while addressing the 
primary study aims, and a Bonferroni correction applied with effects reported at a .0125 
(.05/4) level of significance. Effect size values were calculated as follows: r = Z/√n, with 
r values above 0.1 representing a small effect size, values above 0.3 representing a 
medium effect size, and values above 0.5 representing a large effect size.  
Results indicated that MSIF scores did not differ between the BNR patient group 
and both the NaNR patient group (U = 128.5, p > .05, r = -.097), and the BrNR patient 
group (U = 72.0, p > .05, r = -.067). When comparing the patients with the controls, 
results indicated that MSIF global scores were significantly higher among the NaNR 
patient group as compared to the NR control group (U = 49.5, p < .01, r = -.75), and 
MSIF scores were also significantly higher among the BrNR patient group as compared 
to the NR control group (U = 23.0, p < .01, r = -.72) (Table 2). 
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Table 2 
Community Independence and Clinical Data for Below Normal-Range (BNR) Patients, 
Narrow Normal-Range (NaNR) Patients, Broad Normal-Range (BrNR) Patients, and 
Normal-Range (NR) Controls  
 
Variable 1. BNR 
Patients 
(n = 13) 
2. NaNR 
Patients  
(n = 25) 
3. BrNR 
Patients  
(n = 13) 
4. NR 
Controls 
(n = 25) 
Statistic Post-hoc  
MSIF 
Global 
Scores, 
(M, SD) 
 
4.17 
(1.40) 
3.88 
(1.04) 
4.00 
(1.16) 
1.80  
(.86) 
H(3) = 
36.80 ** 
2, 3 > 4 
1 = 2 = 3 
PANSS 
Positive T 
(M, SD) 
 
47.46 
(9.12) 
46.36 
(8.22) 
44.31 
(7.81) 
n/a λ = .92 n/a 
PANSS 
Negative T 
(M, SD) 
 
44.31 
(10.16) 
40.04 
(6.96) 
38.77 
(8.68) 
n/a λ = .92 n/a 
Note: MSIF = Multidimensional Scale of Independent Functioning; PANSS = Positive 
and Negative Syndrome Scale.  
** p < .001 
 
Clinical implications of NaNR and BrNR subtypes  
Assumptions for MANOVA were assessed. All observations were statistically 
independent, and data were randomly sampled from the population. Based on 
Mahalanobis distance (df = 2, cut off = 13.82), there were no multivariate outliers among 
the residuals (all values were less than 8.718). Multivariate normality was assessed in R 
Studio using Mardia’s multivariate test of normality. Based on the residuals of PANSS 
Positive and Negative T scores, the Skewness (Mardia’s = 6.01, p = .20) and Kurtosis 
(Mardia’s = -.81, p = .42) indicated multivariate normality. Box’s test of equality of 
covariance matrices was not violated (M = 12.43, F(6, 16693.13) = 1.93, p = .072).  
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The MANOVA, with patient group (i.e., BNR, NaNR, and BrNR) set as the 
independent variable, and the PANSS Positive and Negative T scores set as dependent 
variables, did not show a significant difference between patient groups in terms of 
symptom severity (λ = .92, F (4, 94) = .994, ηP2 = .041, p = .415).  Therefore, BNR, 
NaNR and BrNR patient groups did not differ in terms of their positive and negative 
symptom severity (Table 2).  
Summary 
Study 1 assessed the prevalence and clinical and functional validity of two 
definitions of cognitive normality: i) a narrow definition (i.e., WASI Two-Subtest IQ 
score equal to or between 90 and 109) and ii) a broad definition (i.e., MCCB composite T 
score between 40 and 60). Participants included 99 patients with schizophrenia or 
schizoaffective disorder and 80 healthy controls. Prevalence rates of cognitive normality 
ranged from 14% (MCCB broad normal-range) to 48% (IQ narrow normal-range). 
Regardless of the cognitive normality criteria applied, cognitively normal patients were 
functionally disadvantaged, based on MSIF scores, relative to cognitively normal 
controls. They demonstrated no advantage in functionality or clinical symptom severity, 
based on PANSS symptom scores, relative to cognitively impaired patients. A full 
discussion pertaining to the findings and implications of Study 1 is presented in the 
Discussion section, beginning on page 62.   
Study 2 
 As previously described, the purpose of Study 2 was to evaluate Keefe et al.’s 
(2005) cognitive function decrement algorithm and to examine the clinical and functional 
implications of being a “truly” cognitively normal patient.  
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Hypotheses 
It was predicted that findings by Keefe et al. (2005) pertaining to their definition 
of a cognitive function decrement would be replicable in our sample. If “truly” normal 
patients emerged who have not experienced a cognitive function decrement, it was 
hypothesized that they would have a functional advantage relative to patients who have 
experienced a cognitive function decrement, but that patients in the two groups would not 
differ in terms of symptom severity. It was also expected that prevalence rates emerging 
in Studies 1 and 2 would vary as a result of the stringency of the definition, with the 
following prevalence rates: NaNR > BrNR > Non-Decrement Subtype.  
Methods 
Participants  
Participants in Study 2 included 156 patients (99 males, 57 females) who met 
diagnostic criteria for schizophrenia (n = 95) and schizoaffective disorder (n = 61) and 74 
controls (56 males, 18 females). Medical chart review indicated that 152 patients were 
receiving antipsychotic medication at the time of data collection, with 129 patients 
treated with second-generation drugs. Diagnosis was confirmed by the Structured 
Clinical Interview for DSM-IV-TR Axis I Disorders (First et al., 1996). The same 
inclusion criteria for patients and controls were applied to Study 1 and Study 2. Patients 
were recruited from outpatient settings in south central Ontario, and controls were 
recruited by postings for paid research participation in community newspapers.  
Measures 
Current clinical state and severity were evaluated with the Positive and Negative 
Syndrome Scale (PANSS; Opler et al., 1999). Community independence was measured 
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with the overall global rating from the Multidimensional Scale of Independent 
Functioning (MSIF; Jaeger, Berns, Multidimensional, & Functioning, 2003) in both 
patients and healthy controls. As mentioned, the MSIF global rating reflects the level of 
functioning across residential, work, and educational settings while considering role 
position, level of performance, and degree of assistance required. Scores range from one 
to seven, with higher scores indicating greater dependency.  
Premorbid ability was estimated with the Wide Range Achievement Test Reading 
subtest, 3rd Edition (WRAT-3; Snelbaker, Wilkinson, Robertson, & Glutting, 2001). 
Participants provided data pertaining to the highest grade of education achieved by either 
parent.  
Keefe et al.’s (2005) composite z-scores were based on a cognitive battery 
assessing domains of verbal memory, working memory, motor function, processing 
speed, attention, and reasoning and problem solving abilities (Keefe et al., 2004). To 
replicate Keefe’s calculation of the composite z-score as closely as possible, measures 
from our cognitive test battery that assessed analogous domains were used. Specifically, 
calculation of the composite z -score in the current study was based on the following 
cognitive measures: i) California Verbal Learning Test Trials 1-5 Total raw score  
(measure of verbal memory) (CVLT-II: Delis, Kramer, Kaplan, & Ober, 2000); ii) 
Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III: Wechsler, 1997) Letter-
Number Sequencing raw score (measure of working memory); iii) WAIS-III Symbol 
Search raw score (measure of processing speed); iv) Conners’ Continuous Performance 
Test Omission errors raw (measure of attention) (CPT-II: Conners, 2000); and v) WAIS-
III Matrix Reasoning raw score (measure of reasoning and problem solving). The 
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cognitive battery administered as part of the current study did not include a measure of 
motor function, unlike Keefe et al.’s (2005) study.  
Statistical Analyses 
Calculation of the composite z-score included the following steps: i) z-score 
calculation for each of the five raw test scores, based on the healthy control mean and 
standard deviation; ii) calculation of the mean of the five z-scores; iii) z-score of the 
mean of the z-scores was calculated to represent the composite z-score.  
Following methods by Keefe et al., (2005), three linear regression analyses were 
performed on the control population to determine the predicted cognitive composite z-
score based on the i) highest educational grade achieved by either parent; ii) WRAT-3 
Reading scores; and iii) highest parental education and WRAT-3 Reading scores. 
Cognitive function decrement was defined as a composite z-score falling below the 
regression line. In line with methods by Keefe et al., (2005), a one-tailed 95% confidence 
interval was calculated for the regression line for each of the three models. A one-tailed 
confidence interval was used because their hypothesis regarded only the accuracy of 
estimates for the lower side of the regression line, that is for patients who performed 
worse than expected (i.e., cognitive decrement subgroup). The proportion of patients 
meeting this definition of cognitive decrement, and the proportion of patients meeting a 
definition of no cognitive decrement (i.e., performing at or above the regression line) 
were calculated for each of the three regression models. The participants who performed 
worse than expected were classified as having experienced a cognitive decrement, 
whereas those who performed at or above expectations were classified as belonging to 
the non-decrement group. The proportion of patients and controls whose cognitive 
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composite scores fell within the range of the 95% one-tailed confidence interval on the 
lower side of the regression line was reported, and these participants were not included in 
subsequent analyses comparing decrement vs. non-decrement subtypes. 
To assesses the prevalence and functional implications of cognitively normal 
patients who have not experienced a cognitive function decrement, patients and controls 
were further classified based on their composite z-scores and were included in further 
analyses if their performance fell within the average-range (AR). According to z-scores 
and their performance relative to the regression line, patients were classified as: i) AR 
(i.e., z-scores between -0.67 and +0.67) non-decrement; or ii) AR decrement (i.e., z-
scores between -0.67 and +0.67, but with their composite z-score falling below predicted 
values). The same classification criteria were applied to controls to generate i) AR non-
decrement controls and ii) AR decrement controls. The z-score normality criterion of less 
than 0.67 and greater than -0.67 was selected to reflect average-range performance 
according to the Wechsler qualitative descriptors and the corresponding scaled scores of 
8 to 12.  
Functional and Clinical Implications of the Non-Decrement Subtype 
To assess functional and clinical implications of having experienced a cognitive 
decrement, analysis included a univariate ANOVA to compare the effect of cognitive 
decrement group on community outcome, with post-hoc multiple comparisons conducted 
to explore any main effects. For symptom severity, a one-way MANOVA was conducted 
among the schizophrenia group, setting Cognitive Decrement as a fixed factor (i.e., Yes 
or No), and PANSS positive and negative symptoms as dependent variables.  
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These analyses were conducted again among patients and controls who have and 
have not experienced a cognitive decrement, and who also performed within the average-
range based on their composite z-scores.  
Results 
Predicted Composite z-score 
The means and standard deviations among the healthy control group, whose data 
were used to calculate the composite z-score used in the prediction models, were as 
follows: i) CVLT Trials 1-5 Total raw (M = 50.88, SD = 11.23); ii) WAIS-III Letter-
Number Sequencing raw (M = 11.18, SD = 3.03); iii) WAIS-III Symbol Search raw (M = 
29.59, SD = 10.04); iv) CPT-II Omission errors raw (M = 3.31, SD = 7.31); and v) 
WAIS-III Matrix Reasoning raw (M = 17.45, SD = 4.87).  
WRAT-3 Reading Score as a Predictor  
Assumptions of multiple regression were assessed for the model with WRAT-3 
Reading scores set as a predictor of composite z-scores (among healthy controls). 
Residual values were normally distributed, errors were independent based on a Durbin-
Watson test (p = .584), component plus residual plots confirmed that the linearity 
assumption was met, and there was no evidence of heteroscedasticity based on the non-
constant variance score test (p = .80). No outliers were identified in the data. 
WRAT-3 Reading scores explained 11.5% of the variance in cognitive composite 
scores (R2 = .115, F(1,72) = 9.36, p < .01). WRAT-3 Reading was a significant predictor 
of composite z-scores (β = .339, t = 3.06, p < .01).  
Predicted composite z-score values among the patient and healthy control groups 
were obtained using the Predict method for linear model fits in R Studio based on the 
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linear model obtained from the healthy control data. The regression equation was as 
follows: 
Yi = b0 + b1Xi1  
composite scorei = -1.913 + .0507 (WRAT-3) 
When WRAT-3 Reading scores were used in the regression equation, 69.2% (n = 
108) of patients had cognitive composite scores falling below the regression line, and 
19.2% (n = 30) performed above expected levels. Eighteen patients (11.5%) had 
cognitive composite scores that fell within the range of the 95% one-tailed confidence 
interval. Among controls, 39.2% (n = 29) had cognitive composite scores falling below 
the regression line, and 54.1% (n = 40) had scores falling above the regression line (see 
Figure 1). A total of 5 controls (6.8%) performed within the range of the 95% one-tailed 
confidence interval and they were therefore not included in either the decrement or no-
decrement group. 
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Figure 1. Cognitive Composite Score Predicted by WRAT-3 Reading Scores.  The 
curved lined represents the 90% confidence interval of the regression line, with 
participants falling within the lower bounds excluded from analysis. Participants falling 
above the regression line performed above the expectations based on their WRAT-3 
Reading scores, and those falling below the regression line performed below 
expectations.  
 
Parental Education as a Predictor 
Assumptions of linear regression were assessed for this model that included 
parental education as a predictor of composite z-scores (among healthy controls). 
Residual values were normally distributed, errors were independent based on a Durbin-
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Watson test (p = .89), component plus residual plots confirmed that the linearity 
assumption was met, and there was no evidence of heteroscedasticity based on the non-
constant variance score test (p = .91). No outliers were identified in the data. Years of 
parental education explained 5.9% of the variance of cognitive composite scores (R2 = 
.059, F(1,62) = 3.82, p = .055). Parental education was a marginally significant predictor 
of composite z-scores (β = .243, t = 1.96, p = .055). 
The highest number of years of education achieved by patients’ parents were 
applied to the regression equation obtained from the healthy control population to 
determine whether patients performed above or below the expected cognitive composite 
score. The regression equation was as follows: 
Yi = b0 + b1Xi1  
composite scorei = -.0833 + .05333 (Parental Education) 
When years of parental education were used in the regression equation, 70.9% (n 
= 100) of patients had cognitive composite scores falling below the regression line and 
16.3% (n = 23) performed above expected levels. Eighteen patients (12.8%) had 
composite cognitive scores falling within the 95% one-tailed confidence interval below 
the regression line. Among controls, 36.5% (n = 23) had composite scores falling below 
the regression line, and 54.0% (n = 34) performed above the expected value (see Figure 
2). Six controls (9.5%) had composite z-scores falling within the 95% one-tailed 
confidence interval below the regression line.  
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Figure 2. Cognitive Composite Score Predicted by Parental Education (Highest 
Level Achieved by Either Parent).  The curved lined represents the 90% confidence 
interval of the regression line, with participants falling within the lower bounds excluded 
from analysis. Participants falling above the regression line performed above the 
expectations based on their parents’ highest level of education, and those falling below 
the regression line performed below expectations.   
 
WRAT-3 Reading Scores and Parental Education as Predictors 
Assumptions of multiple linear regression among healthy controls with both 
WRAT-3 Reading and parental education set as predictors demonstrated that residual 
values were normally distributed (based on the Normal Q-Q plot), errors were 
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independent based on a Durbin-Watson test (p = .812), component plus residual plots 
confirmed that the linearity assumption was met, and there was no evidence of 
heteroscedasticity based on the non-constant variance score test (p = .75). No outliers 
were identified in the data. 
When both WRAT-3 Reading score and parental education were used in the 
regression equation to predict the cognitive composite score, the two predictors explained 
18.3% of the variance (R2 = .183, F(2,60) = 6.72, p < .01). Parental education 
significantly predicted composite z-scores (β = .233, t = 2.0, p = .05), as did WRAT-3 
Reading scores (β = .352, t = 3.02, p < .01).  
Patient WRAT-3 Reading scores and parental education were applied to the 
regression equation obtained from the healthy control population to determine whether 
patients performed above or below the expected cognitive composite score. The 
regression equation was as follows: 
Yi = b0 + b1Xi1 + b2Xi2 
composite scorei = -2.700 + .05343 (WRAT-3) + .05128 (Parental Education) 
  Based on the linear model with both parental education and reading scores set as 
predictors, 62.1% (n = 87) of patients failed to perform at the expected level on the 
cognitive composite score, and 21.4% (n = 30) performed above the expected level. A 
total of 23 patients (16%) performed within the range of the 95% one-tailed confidence 
interval and they were therefore not included in either the decrement or no-decrement 
group. Among controls, 41.3% (n = 26) failed to perform at the expected level, and 
58.7% (n = 37) performed above the expected level.  
Patient classification based on the combination of WRAT-3 Reading and parental 
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education as predictors will be used for subsequent analysis of functional and clinical 
validity of the non-decrement patient subtype, as this regression model is both the most 
comprehensive (as it includes two predictors), and it also has the smallest Akaike 
Information Criterion (AIC) value (WRAT-3 Reading as a predictor AIC = 149.65; 
parental education as a predictor AIC = 130.99; WRAT-3 Reading and parental education 
as predictors AIC = 124.09).  
Comparison with Keefe et al., (2005): Proportion of Cognitive Decrement 
 A Fisher’s Exact test was conducted to compare the frequency of patients who 
have/ have not experienced a cognitive function decrement between the current study and 
Keefe et al., (2005), according to the regression model with both WRAT-3 Reading 
scores and parental education set as predictors. Results indicated that there was a 
significant association between the research study and whether or not patients were 
classified as having experienced a cognitive decrement p < .001 (see Table 3). 
Calculation of the odds ratio demonstrated that if a participant was in the Keefe et al., 
(2005) study, they were 18 times more likely to have experienced a cognitive function 
decrement than if they had participated in the current study. 
Table 3 
Contingency Table Showing the Proportion of Participants that were Classified as 
Having Experienced a Cognitive Function Decrement in the Current Research Study and 
Keefe et al. (2005).   
                                                                       Research Study 
  Keefe et al. (2005) Current Study  Total 
Cognitive Decrement? Yes 105 87 214 
 No 2 30 32 
 Total 107 117 246 
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Functional and Clinical Validity of the Non-Decrement Subtype 
  Given the low prevalence (n = 30) of the non-decrement patient group, and to 
ensure demographic similarity with comparison subgroups, these patients’ age range and 
sex proportion were used as criteria in assigning controls to the non-decrement group, 
controls to the decrement group, and patients to the decrement group for statistical 
analyses. Table 4 shows the descriptive statistics for all four study groups, after 
classification based on age and sex matching. Patients and control subgroups did not 
differ significantly with respect to age, sex distribution, years of parental education, or 
proportion who learned English as their first language. Patients in the cognitive 
decrement subgroup had significantly lower WRAT-3 Reading scores as compared to 
healthy controls in the non-decrement subgroup (t(118) = -3.08, p < .01). High school 
completion rates were equivalent in non-decrement patients and decrement patients. 
However, high school completion rates were lower among patients with a decrement 
compared to controls with a decrement (FET p < .05) and controls without a decrement 
(FET p < .05). High school completion rates were also lower among patients without a 
decrement compared to controls with a decrement (FET p < .05) or without a decrement 
(FET p < .01). As well, patients with a cognitive decrement had significantly lower 
composite z-scores compared to patients without a cognitive decrement (t(115) = -11.24, 
p < .01), and controls without a cognitive decrement (t(118) = -14.26, p < .01). Further, 
patients without a cognitive decrement had significantly higher composite z-scores than 
controls who have experienced a decrement (t(48) = 6.16, p < .01). Lastly, controls 
without a cognitive decrement had significantly higher composite z-scores compared to 
controls with a cognitive decrement (t(51) = -8.98, p < .01).  
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Table 4 
Demographic and Clinical Variables for Patients and Controls Classified as Decrement 
or No Decrement According to Parental Education and WRAT-3 Reading as Predictors 
of Cognitive Performance 
 
 SCZ with 
Decrement  
(n = 87) 
SCZ 
without 
Decrement  
(n = 30) 
Controls with 
Decrement 
(n = 20) 
Controls 
without 
Decrement  
(n = 33) 
Test Statistic 
Age, yrs  
(M, SD) 
 
41.74 
(9.17) 
37.87 
(10.32) 
42.95  
(11.56) 
37.73  
(12.32) 
F (3, 166) = 
2.130 
Sex  
(males %) 
 
68.9% 46.7% 80.0% 72.7% FET = 7.31 
WRAT-3 
Reading 
Score Raw 
(M, SD) 
 
46.49 
(5.82) 
46.40  
(6.89) 
48.75  
(3.29) 
50.00  
(4.81) 
F (3, 166) = 
3.815 * 
Parental 
Education 
(M, SD) 
 
13.30 
(4.17) 
11.8  
(4.03) 
13.18  
(3.03) 
12.58  
(3.20) 
F (3, 165) = 
1.238 
High School 
Completion 
(%) 
 
67.8% 73.3% 100% 96.7% FET = 
20.812** 
First 
Language 
English (%) 
 
85.0% 73.3% 75.0% 72.7% χ2 (3) = 3.51 
Composite 
z-score  
(M, SD) 
 
-0.67 
(0.88) 
0.74  
(0.46) 
-.06  
(0.45) 
1.01  
(0.41) 
F (3, 166) = 
60.64** 
Note: FET = Fisher’s Exact Test; M = mean; SCZ = schizophrenia; SD = standard 
deviation; WRAT-3 = Wide Range Achievement Test – 3rd Ed. 
** p < .001  * p < .05 
 
To assess whether MSIF global scores differed significantly between groups, 
assumptions for a one-way ANOVA were tested, setting MSIF scores as the dependent 
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variable, and group (i.e., i) schizophrenia with decrement; ii) schizophrenia without 
decrement; iii) HC with decrement; iv) HC without decrement) as the independent 
variable.  Bartlett’s test indicated that the variances in the four groups did not differ 
significantly (p = .11). There was no indication of outliers in the MSIF data. Visual 
inspection of Q-Q plot indicated that residuals of MSIF scores showed mild deviation 
from normality, yet there was not strong evidence that transformation was required 
because the hypothesis that λ = 1 was not rejected (p = .88) (based on the 
PowerTransform function carried out in R Studio, which generates a maximum-
likelihood estimation of the power λ most likely to normalize the variable). Taken 
together, the data appeared to fit the ANOVA model.  
The univariate F ratio showed a significant group difference for the MSIF scores. 
Additional testing of group means was carried out using Tukey HSD testing, adjusted for 
multiple comparisons. Results indicated that MSIF scores were significantly higher 
among patients who have experienced a cognitive decrement as compared to patients who 
have not experienced a cognitive decrement, as well as both control groups. Patients who 
have not experienced a cognitive decrement, however, had significantly higher MSIF 
scores than both control groups, suggesting that they remained at a functional 
disadvantage relative to controls, despite their functional advantage relative to patients 
who have experienced a decrement. The two control groups did not differ in terms of 
their MSIF scores (see Table 5). 
To assess the effect of cognitive decrement on symptom severity (i.e., PANSS 
Positive and Negative symptom T scores) among the patients with schizophrenia, 
assumptions for MANOVA were first assessed. All observations were independently 
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distributed and symptom severity scores were continuous. Based on Mahalanobis 
distance (df = 1, cut off = 10.828), there were no multivariate outliers among the 
residuals (all values were less than or equal to 10.8). An assessment of multivariate 
normality was conducted in R Studio using Mardia’s multivariate test of normality. 
Based on the residuals of the PANSS positive and negative T scores, the skewness 
(Mardia’s = 5.48, p = .24) and kurtosis (Mardia’s = -.09, p = .93) estimates indicated that 
the distribution of residuals was multivariate normal. Visual inspection of a chi-square Q-
Q plot suggested a mild deviation from normality. Box’s test of equality of covariance 
matrices was not violated (M = .373, F(3, 48899.60) = .121, p = .95).  
The MANOVA, with patient group (i.e., patient group with decrement, patient 
group without decrement) set as the independent variable, and the PANSS Positive and 
Negative T scores set as dependent variables, showed a significant difference between 
patient groups in terms of symptom severity (λ = .94, F (2, 114) = 3.92, ηP2 = .064, p = 
.023).  Follow-up one-way ANOVAs indicated that groups did not differ significantly in 
terms of PANSS positive symptoms severity (p = .09), but the patients with a cognitive 
decrement reported significantly greater PANSS negative symptom severity relative to 
the group who had not experienced a cognitive decrement (F(1,115) = 6.24, ηP2 = .052, p 
= .014) (Table 5).  
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Table 5 
Community Independence and Clinical Variables among the Subgroups with and without 
Cognitive Decrements 
 
Variable 1. SCZ 
with 
Decrement  
(n = 87) 
2. SCZ 
without 
Decrement  
(n = 30) 
3. Controls 
with 
Decrement 
(n = 20) 
4. Controls 
without 
Decrement  
(n = 33) 
Statistic Post hoc  
MSIF 
Global 
Scores, 
(M, SD) 
 
4.68 (0.99) 3.93  
(1.14) 
2.10  
(1.37) 
1.58  
(1.03) 
F(3,166
) = 
81.67*
* 
1>2,3,4 
2>3,4 
3=4 
 
PANSS 
Positive T 
(M, SD) 
 
50.55 
(8.74) 
47.37 
(9.00) 
n/a n/a Wilk’s 
λ = 
.94* 
 
1=2 
PANSS 
Negative 
T (M, SD) 
46.89 
(9.55) 
41.93 
(8.76) 
n/a n/a Wilk’s 
λ = 
.94* 
1>2 
Note: MSIF = Multidimensional Scale of Independent Functioning; PANSS = Positive 
and Negative Syndrome Scale; SCZ = schizophrenia.  
** p < .001 
 
Functional and Clinical Validity of the “Truly Normal” Average-Range Non-
Decrement Subtype 
Clinical and demographic characteristics of the average-range (AR) patient and 
control subgroups are presented in Table 6. Groups did not differ with respect to age. AR 
decrement patients had a significantly higher proportion of males compared to the AR 
non-decrement patients (FET p < .05), but the AR decrement patients did not differ from 
the AR decrement and non-decrement control groups in terms of sex distribution. The 
non-decrement AR patients had a significantly higher proportion of females compared to 
the non-decrement AR controls (FET p < .05), and compared to the controls who 
experienced a cognitive decrement in terms of sex distribution. (FET p < .05) 
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To assess whether MSIF global scores differed significantly between groups, 
assumptions for a one-way ANOVA were tested, setting MSIF scores as the dependent 
variable, and group (i.e., i) AR schizophrenia with decrement; ii) AR schizophrenia 
without decrement/ “truly normal”; iii) AR control with decrement; iv) AR control 
without decrement) as the independent variable.  Bartlett’s test indicated that the 
variances in the four groups differed significantly (p = .03). There was no indication of 
outliers in the MSIF data. Visual inspection of Q-Q plot indicated that residuals of MSIF 
scores show some deviation from normality. Due to violations of homogeneity of 
variances, and deviation of residuals from normality, data were analyzed using a non-
parametric Kruskal-Wallis test to compare the effect of group (i.e., AR patients with 
decrement, AR patients without decrement, AR controls with decrement, and AR controls 
without decrement) on community outcome (i.e., MSIF global scores), with post-hoc 
Mann-Whitney tests conducted with Bonferroni correction.  
MSIF scores were significantly affected by participant group (H(3) = 30.26, p < 
.001). Mann-Whitney tests were used to follow up on this finding based on the following 
comparisons: i) AR decrement patients vs. AR non-decrement patients (i.e., “truly 
normal”); and ii) AR non-decrement patients (i.e., “truly normal”) vs. AR non-decrement 
controls, with only these select Mann-Whitney tests chosen to reduce the Type I error 
rate while addressing the primary study aims, and a Bonferroni correction applied with 
effects reported at a .025 level of significance (.05/2). 
Results indicated that MSIF scores did not differ between the AR decrement 
patient group and the AR non-decrement patient group (U = 305.50, p > .05, r = -.07). 
However, AR non-decrement patients reported significantly higher MSIF scores as 
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compared to the AR non-decrement controls (U = 11.50, p = .012, r = -.57), suggesting 
poorer community independence among “truly normal” patients compared to “truly 
normal” control participants (Table 6). 
To assess the effect of cognitive decrement on symptom severity among patients 
performing within the average range, assumptions for MANOVA were first assessed. All 
observations were independently distributed and symptom severity scores were 
continuous. Based on Mahalanobis distance (df = 1, cut off = 10.828), there were no 
multivariate outliers among the residuals (all values were less than or equal to 10.2). An 
assessment of multivariate normality was conducted in R Studio using Mardia’s 
multivariate test of normality. Based on the residuals of the PANSS positive and negative 
T scores, the skewness (Mardia’s = 1.84, p = .76) and kurtosis (Mardia’s = .18, p = .85) 
estimates indicated that the distribution of residuals was multivariate normal. Visual 
inspection of a chi-square Q-Q plot suggested a mild deviation from normality. Box’s test 
of equality of covariance matrices was not violated (M = 3.04, F(3, 6546.59) = .950, p = 
.42).  
A MANOVA was performed with patient group (i.e., AR patient group with 
decrement, AR patient group without decrement) set as the independent variable, and the 
PANSS Positive and Negative T scores set as dependent variables. Results indicated that 
AR patients who have experienced a cognitive decrement do not differ from AR patients 
without a cognitive decrement (i.e., “truly normal”) with respect to their self-reported 
severity of positive or negative symptoms (F(1, 62) = .809, ηP2 = .025, p = .45) (see Table 
6).  
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Table 6 
Demographic, Community Independence, Clinical Variables among the Average-Range 
Subgroups with and without Cognitive Decrements 
 
Variable 1. SCZ 
AR with 
Decrement  
(n = 52) 
2. SCZ AR 
without 
Decrement  
(n = 13) 
3. Controls  
AR with 
Decrement 
(n = 18) 
4. Controls  
AR without 
Decrement  
(n = 6) 
Statistic Post hoc  
Age  
(M, SD) 
40.85 
(9.82) 
40.15 
(11.34) 
43.78 
(11.65) 
46.50 
(11.57) 
F(3,85) = 
.855 
n/a 
Sex  
(males %) 
 
69.2% 30.7% 77.7% 100% FET = 
10.72*
* 
 
MSIF 
Global 
Scores, 
(M, SD) 
 
4.42 
(1.00) 
4.23  
(.73) 
2.11  
(1.45) 
2.17  
(1.60) 
H(3) = 
30.26*
* 
1=2 
2>4 
PANSS 
Positive T 
(M, SD) 
48.79 
(8.01)  
50.15 
(8.06) 
n/a n/a Wilk’s 
λ = 
.975 (p 
= .45) 
 
n/a 
PANSS 
Negative T 
(M, SD) 
45.90 
(8.79) 
43.08 
(5.79) 
n/a n/a Wilk’s 
λ = 
.975 (p 
= .45) 
 
n/a 
Note: FET = Fisher’s Exact Test; MSIF = Multidimensional Scale of Independent 
Functioning;  
PANSS = Positive and Negative Syndrome Scale.  
** p < .001     * p < .05 
 
Post-Hoc Analysis of Functional and Clinical Implications of Above Average-Range, 
Non-Decrement Patients 
 Given that non-decrement patients reported less dependency on the MSIF and less 
severe negative symptoms on the PANSS compared to decrement patients when the 
entire sample was combined (first analysis), but not when only AR patients were assessed 
(second analysis), post-hoc analyses were conducted to determine if perhaps the above-
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AR patients who were not included in the second analysis were driving the finding in the 
first analysis. A total of 12.1% of patients were classified as above average-range (i.e., 
composite z-score > .67) without having experienced a decrement. Above-AR patients 
without a cognitive decrement (MSIF Mean = 3.71, SD = 1.36) showed a functional 
advantage relative to AR patients with a cognitive decrement (MSIF Mean = 4.42, SD = 
1.0) (U = 300.5, r = -.25, p = .041). AR patients with and without a cognitive decrement, 
and above-AR patients without cognitive decrement, however, all remained functionally 
disadvantaged compared to cognitively NR and above-NR controls (ps < .05).  
 Further, above-AR patients without a cognitive decrement showed a clinical 
advantage relative to AR patients with a decrement. Specifically, above-AR non-
decrement patients reported a reduced severity of negative symptoms on the PANSS 
(Mean = 41.2, SD = 10.59 relative to AR patients with a decrement (Mean = 45.9, SD = 
8.79) (U = 306.5, r = -.22, p = .059). Notably, however, this finding was only 
approaching significance.  
Prevalence of Normal/ Non-Decrement Patients in Studies 1 and 2 
 Based on findings from Studies 1 and 2, the prevalence of cognitive normality/ 
lack of cognitive decrement varies depending on the criteria applied. Specifically, 
prevalence rates vary from 9.3% to 48%, depending on the classification used (See 
Figure 3). 
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Figure 3. Prevalence of patients meeting criteria for cognitive normality according to two 
distinct classification methods (Study 1) and prevalence of patients who did not 
experience a cognitive decrement based on predictive models (Study 2).  
Note: WRAT-3 = Wide Range Achievement Test – 3rd Ed. 
Summary 
Study 2 evaluated a cognitive decrement algorithm (Keefe et al., 2005) and its 
clinical and functional validity among 156 patients and 74 controls. Following methods 
by Keefe et al., (2005), a cognitive decrement was defined as current cognitive 
performance falling below expected levels based on estimates of premorbid intellectual 
ability (e.g., parental education and reading scores).  Patients were classified as having 
average-range cognition with a decrement (37.1%), average-range cognition without a 
decrement (9.3%), and above-average range cognition without a decrement (12.1%), 
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confirming the existence of “truly” cognitively normal (or above-average range) patients 
who show no evidence of a decline relative to premorbid estimates. However, these 
patients were relatively rare (prevalence of 9-12%), and less common than some previous 
estimates. Average-range patients without a decrement did not show a functional (i.e., 
MSIF scores) or clinical (i.e., PANSS scores) advantage relative to average-range 
patients demonstrating a decrement. The combination of both above-average range 
cognition and lack of a cognitive decrement, however, conferred a functional advantage 
among patients (with a finding pertaining to reduced negative symptom severity among 
this above-average group approaching significance). However, these high-functioning 
patients remained functionally disadvantaged relative to controls. A discussion pertaining 
to the findings and implications of Study 1 is presented in the Discussion section, 
beginning on page 62.   
Study 3 
As previously discussed, the purpose of this study was to assess the incremental 
validity of the Breakfast Task in predicting disability relative to standard measures of 
cognition and symptom severity.  
Hypotheses 
It was predicted that patients with schizophrenia would perform more poorly than 
healthy controls on The Breakfast Task. Among the patient group, it was expected that 
the Breakfast Task would have greater predictive validity of disability relative to standard 
measures of cognition and symptom severity.  
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Methods 
Participants 
Participants in Study 3 included 30 patients (19 males and 11 females) with a 
diagnosis of schizophrenia (n = 21) or schizoaffective disorder (n = 9) and 37 non-
psychiatric controls (20 males and 17 females). Thirty patients were receiving 
antipsychotic medication at the time of data collection, with 25 patients treated with 
second-generation drugs. Controls were excluded based on a history of a neurological 
disorder, major medical condition, psychiatric illness, or developmental disability. 
Inclusion and exclusion criteria were assessed using a screening questionnaire. Patients 
were recruited through outpatient settings in southern Ontario, and controls were 
recruited by postings and advertisements online and within the community.  
Measures  
The Vocabulary and Matrix Reasoning subtests of the Wechsler Abbreviated 
Scale of Intelligence, Second Edition were administered to obtain a measure of general 
intellectual ability (WASI-II; Wechsler, 2011).  
Psychiatric symptomatology was assessed using the 24-item Brief Psychotic 
Rating Scale (BPRS: Overall & Gorham, 1962). BPRS Positive symptom (bizarre 
behaviour, unusal thought content, disorientation, hallucinations, and suspiciouness) and 
Negative symptom (blunted affect, motor retardation, emotional withdrawal, self-neglect) 
subscales were used in statistical analyses.   
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS 
2.0: Üstün, 2010) was administered to assess disability. The WHODAS 2.0 is a 36-item 
self-report instrument that measures functioning in six domains of life: cognition, 
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mobility, self-care, getting along, life activities, and participation. Summary scores on the 
WHODAS 2.0 range from 0 to 100, with higher scores representing greater levels of self-
reported disability across the six domains. The WHODAS 2.0 Without Work Summary 
score was used for analysis.  
The Breakfast Task 
The Breakfast Task (Craik & Bialystok, 2006) is a computerized working 
memory and executive test that simulates cooking breakfast. A distractor task (i.e., setting 
a table) is included in order to increase demands on prospective memory and planning. 
Participants were instructed that their primary goal was to cook five foods (i.e., eggs, 
sausage, toast, coffee, and pancakes) for the correct specified duration (i.e., avoid over- 
or under-cooking the food) and to have each of the foods prepared at the same time. 
Participants were informed that their secondary goal was to complete as much of the table 
setting as possible. Each of the five foods were shown on the screen with their respective 
required cook time (i.e., 2.5 minutes, 4.5 minutes, 1 minute, 2 minutes, and 3 minutes), 
along with a thermometer indicating the cooking progress for each food, and a “start” and 
“stop” button. Participants used a mouse to click on the start and stop buttons to initiate 
and end the cooking of each food. In order to have all foods finished cooking at the same 
time, participants were required to calculate when to start each food, as there was no 
signal as to when each food item should start its cooking process. The computer program 
recorded the time that the “start” and “stop” buttons were pressed in order to monitor and 
calculate the extent of over- or under-cooking. Regarding the table setting task, 
participants were required to place forks, knives, spoons, and plates arranged at the 
bottom of the screen in their correct positions for four place settings. Items were placed 
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around the table by first using the mouse to click on an item with the cursor, and then 
clicking on its destination on the table. Participants were instructed that once they 
finished setting the last place at the table, all the settings would drop to the bottom of the 
screen, and they would be required to set the table again.  
The Breakfast Task consists of three conditions with varying complexity: i) one-
screen (performed first); ii) two-screen (performed second); and iii) six-screen condition 
(performed last). The one-screen condition consisted of all of the foods and the table 
present on the same screen (Figure 4). In the two-screen condition, the table was shown 
on one screen, whereas the five foods, their cook times and thermometer indicators were 
all shown together on a second screen. Unlike the one-screen condition, the two-screen 
condition required switching between two screens. The six-screen condition consisted of 
one screen showing the table, and five screens each showing a separate food with its 
respective cook time and thermometer indicator. Relative to the one- and two-screen 
conditions, the six-screen condition required the most screen switching and is considered 
the most complex. The one-screen and two-screen conditions were used as practice trials, 
and the results of the six-screen condition were the focus of the present study and 
subsequent analyses.   
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Figure 4. Sample Screen from the One-Screen Condition of the Breakfast Task. This 
shows the five foods to be cooked, the table to be set, and the cooking indicators for each 
of the five foods.  (Reproduced with permission from the Breakfast Task Manual (Craik 
& Bialystok, 2004)).  
 
The primary scores obtained from the Breakfast Task were as follows: i) 
Discrepancy Score (actual time – ideal time); ii) Range Score (time last food stopped – 
time first food stopped); iii) Deviation Score (deviation from ideal start times); and iv) 
Times Checked Score (number of times progress of food checked). In addition to the four 
primary scores, the Number of Table Settings was recorded. Each of the four table 
settings included a plate, fork, spoon, and a knife. Therefore, sixteen table settings were 
required to set the entire table; however, since participants were instructed to continue to 
re-set the table as the task progressed, participants’ Number of Table Settings could be 
greater than sixteen.  
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The Discrepancy Score reflects prospective memory, with a low score suggesting 
one was able to disengage from the table-setting task to tend to the food. The Range 
Score is indicative of planning ability and working memory, with a lower range score 
reflecting a greater ability to account for the varying cooking times for each food. Craik 
and Bialystok (2006) suggest that the Range Score is most reflective of the ability to 
prepare a good meal in real life (i.e., ensuring all foods are ready at the same time). The 
Deviation Score is indicative of planning ability, with lower scores reflecting a better 
ability at ensuring foods finished cooking simultaneously.  The final primary score, the 
Times Checked score, is reflective of monitoring and prospective memory. The Number 
of Table Settings (distractor task) score is associated with executive functions, but not 
prospective memory (Rose et al., 2015). 
Statistical Analyses 
To assess group differences in demographic, psychological, intellectual 
functioning, and disability variables, data were first tested for normality (p > .05, 
Shapiro-Wilk test) and group comparisons were calculated using independent samples t-
tests or Mann-Whitney U test, depending on distribution of data. Group differences in sex 
were assessed with a Chi-Square test, and differences in high school completion were 
assessed with a Fisher’s Exact Test. 
Due to non-normality (p < .05, Shapiro-Wilk test) of the four primary Breakfast 
Task Six-Screen Condition scores, they were log transformed in order to perform 
independent samples t-tests. The log transformation, however, did not result in a normal 
distribution among all of the scores. The scores on these measure were therefore analyzed 
using non-parametric Mann-Whitney U tests, setting Group (i.e., Patient, Healthy 
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Control) as the independent variable, and scores on the Breakfast Task (i) Discrepancy 
Score; ii) Range Score; iii) Deviation Score; and iv) Times Checked Score) as the 
dependent variables. The Number of Table Settings variable was normally distributed (p 
> .05, Shapiro-Wilk test) and an independent samples t-test was therefore conducted to 
assess for group differences. 
Among the patient group, associations between scores on the Breakfast Task and 
clinical (i.e., BPRS Positive and Negative Symptoms) and intellectual functioning (i.e., 
WASI-II 2 subtest IQ) variables were calculated using Spearman’s rho (two-tailed).  
A hierarchical regression was carried out among patients with schizophrenia with 
predictors entered in the following order: i) BPRS Positive and Negative scores; ii) 
WASI-II 2-subtest IQ-scores; and iii) Breakfast Task Six-Screen condition primary 
scores that differ significantly between patient and control groups, with the WHODAS 
2.0 Summary (Without Work) Scores set as the dependent variable.  
Results 
Demographic characteristics of the patient group and comparison controls are 
presented in Table 7. The groups did not differ significantly in age, sex distribution, 
frequency of English as the first language, rates of employment, or high school 
completion. In terms of intellectual functioning, groups did not differ in their WASI-II 2-
subtest IQ scores (p = .089). Groups differed in terms of their self-reported levels of 
disability on the WHODAS 2.0 Summary Without Work Scores (U = 186.5, p < .01, r = -
.55; large effect size). 
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Table 7 
Demographic and Clinical Characteristics of Patients and Controls 
 Schizophrenia (n = 30) Controls (n = 37) 
 Mean (SD) Mean (SD) 
Demographic Variables 
Age, years (Mean, SD) 46.0 (9.5) 45.6 (9.0) 
High school completion, n 
(%) 
24 (80%) 34 (92%) 
Sex (males), n (%) 19 (63%) 20 (54%) 
First language English, n 
(%) 
28 (93%) 29 (78%) 
Employment, n (%) 12 (40%) 18 (49%) 
Clinical Characteristics 
BPRS Positive Symptoms 11.7 (2.5) N/A 
BPRS Negative Symptoms 9.5 (1.5) N/A 
Intellectual Functioning 
WASI-II 2-Subtest IQ  97.2 (16.5) 104.0 (15.2) 
Disability Scores 
WHODAS 2.0 **28.6 (13.1) **11.5 (12.4) 
Note. BPRS: Brief Psychiatric Rating Scale; WASI-II Two-Subtest: Wechsler 
Abbreviated Scale of Intelligence, Matrix Reasoning and Vocabulary; WHODAS 2.0: 
WHO Disability Assessment Schedule 2.0. ** p < .01   * p < .05 
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Group Differences on The Breakfast Task 
On the Breakfast Task, patients performed significantly worse than controls on 
the Range Score (i.e., their ability to ensure all five foods were completed at the same 
time) (U = 243, p = .001, r = -.43; medium effect size). As well, patients completed 
significantly fewer table settings relative to controls (t(65) = -6.5, p = .001, d = 1.5; large 
effect size). Groups did not differ in terms of their performance on the remaining 
Breakfast Task Scores (i.e., Discrepancy, Deviations, and Checked Scores) (see Table 8). 
Table 8   
Breakfast Task Performance  
Breakfast Task Scores  
(Six-Screen Condition) 
(Mean, SD) 
Patients  
(n = 30) 
Controls  
(n = 37) 
p Effect Size 
(r) 
Range  35.0 (47.0) 26.4 (54.9) .001 .42 
Discrepancy   29.0 (43.6) 16.3 (15.2) .830 .04 
Deviation  24.6 (24.9) 35.6 (68.9) .685 .05 
Times Checked 21.4 (5.3) 21.6 (6.2) .909 .01 
Number of Table Settings 18.7 (9.5) 32.8 (8.4) .001 *1.5 
Note: *Cohen’s d 
Association Between Scores on the Breakfast Task, Intellectual Functioning, 
Symptom Severity, and Disability 
 Intellectual functioning and disability correlates emerged in relation to Breakfast 
Task Six-Screen Condition performance scores among the group with schizophrenia (see 
Table 9). Better performance based on the Range, Deviation, and Number of Table 
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Settings Scores scores was associated with higher levels of intellectual functioning (rs = -
.53, p = .006; rs = -.51, p = .005, and rs = .55, p = .002, respectively). Better performance 
based on the Range and Deviation scores was related to lower levels of self-reported 
disability (rs = .40, p = .038; rs = .49, p = .006, respectively). No significant correlations 
emerged between Range and Deviation scores and positive or negative symptom severity. 
As well, no significant correlations emerged between the Breakfast Task Discrepancy and 
Times Checked scores, and symptom, intellectual functioning, or disability variables. 
Exploratory analysis revealed that intellectual functioning did not correlate with 
WHODAS 2.0 disability scores (rs = -.06, p = .76) or BPRS positive (rs = -.27, p = .16) or 
negative (rs = -.24, p = .20) symptoms.  
Table 9   
Correlates of Breakfast Task Scores Among the Patient Group 
 
Note: BPRS: Brief Psychiatric Rating Scale; WASI-II Two-Subtest: Wechsler 
Abbreviated Scale of Intelligence, Matrix Reasoning and Vocabulary; WHODAS 2.0: 
WHO Disability Assessment Schedule 2.0. 
All correlation values are Spearman’s correlation coefficients.  
* p < .05    ** p < .01 
 
 BPRS 
Positive 
Symptoms 
BPRS 
Negative 
Symptoms 
WASI-II IQ WHODAS 2.0 
Summary 
Without Work 
Breakfast Task     
     Range +.06 +.10 **-.53 *+.40 
     Discrepancy  +.39 +.46 -.31 -.08 
     Deviation +.16 +.05 **-.51 **+.49 
     Times Checked -.13 -.10 -.16 +.04 
     Number of Table                
     Settings 
-.08 -.18 **.55 -.27 
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Incremental Validity of the Breakfast Task  
 
Assumptions for regression were assessed. Based on Mahalanobis distance (df = 
4, cut off = 18.47), no multivariate outliers were identified amongst the residuals. 
Overall, only one case had extreme influence (Cook’s distance value = 1.060), and 
extreme leverage (hat value = .735), with a Leverage cut-off value of .60 (((k+1)/n) x3) 
(Stevens, 2002). The hierarchical regression analysis was conducted twice, first with the 
outlier case included, and then with the outlier case excluded.  
Assumptions for multiple regression were assessed for the model that included the 
outlier case. There was no multicollinearity (VIF range from 1.0 – 1.4), there was 
independence of errors (Durbin-Watson = 1.570), the residuals were normally distributed, 
and there was no evidence of heteroscedasticity. Incremental validity of the Breakfast 
Task Six-Screen Condition Range score, relative to symptom and intellectual functioning 
data was evaluated using hierarchical regression. First, the WHODAS 2.0 Summary 
Without Work score was regressed on a block of symptom variables consisting of the 
BPRS Positive and Negative Symptoms. This yielded a non-significant F Ratio (F(2,22) 
= .66, ns) and accounted for 5.7% of the variance in WHODAS 2.0 scores. Next, the 
WASI-II 2-subtest IQ estimate was entered into the model. The addition of IQ into the 
model failed to add significantly to the validity (Fchange (1,21) = .018, ns). Finally, the 
Breakfast Task Range scores were entered into the model, which resulted in a significant 
increase in validity (Fchange (1,20) = 4.75, p = .04). The complete model accounted for 
23.9% of the variance in WHODAS 2.0 Summary Without Work scores (see Table 10).  
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Table 10 
Disability Scores Regressed Hierarchically on Symptoms, Intellectual Functioning, and 
Breakfast Task Performance Among Patients with Schizophrenia 
 
Predictor Variables Step 1 Beta Step 2 Beta Step 3 Beta 
BPRS Positive Symptoms .186 .175 .215 
BPRS Negative Symptoms -.137 -.144 -.092 
WASI-II Two-Subtest IQ -- -.031 .234 
Breakfast Task Range Scores -- -- .492 
R2 .057 .058 .239 
R2 Change .057 .001 .181 
Note. BPRS: Brief Psychotic Rating Scale; WASI-II: Wechsler Abbreviated Scale of 
Intelligence. * p < .05 
 
Assumptions for multiple regression were assessed for the model that excluded 
the outlier case. There was no multicollinearity (VIF range from 1.0 – 1.5), there was 
independence of errors (Durbin-Watson = 2.3), the residuals were normally distributed, 
and there was no evidence of heteroscedasticity. 
When the WHODAS 2.0 Summary Without Work score was regressed on a block 
of symptom variables consisting of the BPRS Positive and Negative Symptoms, this 
yielded a non-significant F Ratio (F(2,21) = .66, ns) and accounted for 6.0% of the 
variance in WHODAS 2.0 scores. Next, the WASI-II 2-subtest IQ estimate was entered 
into the model. The addition of IQ into the model failed to add significantly to the 
validity (Fchange (1,20) = .072, ns). Finally, the Breakfast Task Range scores were entered 
into the model, which resulted in a marginally significant increase in validity (Fchange 
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(1,19) = 4.21, p = .054). The complete model accounted for 23.3% of the variance in 
WHODAS 2.0 Summary Without Work scores.   
Summary 
Study 3 assessed the utility of the functionally relevant Breakfast Task (Craik & 
Bialystok, 2006) in predicting disability relative to standard measures of cognition (i.e., 
WASI-II) and symptom severity (i.e., BPRS) among 30 patients and 37 controls. Results 
showed that on the Breakfast Task, patients were impaired relative to controls in their 
ability to ensure all of the foods finish cooking at the same time (Range Score, reflecting 
reflects planning ability and working memory), and they set fewer places at the table 
compared to controls. Further, performance on the Breakfast Task increased the ability to 
predict disability (i.e., WHODAS scores) beyond that provided by standard cognitive 
(i.e., WASI-II) and symptom (i.e., BPRS) measures. A full examination of the findings 
and implications of Study 3 appears in the following Discussion section.  
Discussion  
 
The concept of cognitive normality in patients with schizophrenia is a 
controversial one. It has long been understood that cognitive impairment is a core feature 
of the disorder; yet, subsets of patients, whose performance on standardized cognitive 
tasks overlaps with that of community controls, are repeatedly identified in the literature. 
The prevalence of cognitive normality, with reported rates ranging from 0% (Wilk et al., 
2005) to 55% (Bryson et al., 1993),	is unclear, as are the clinical and functional 
implications of this subgroup. The aim of the present investigation was to estimate the 
prevalence of cognitive normality corresponding to narrow, broad, and non-decrement 
definitions, to examine the clinical and functional validity of each definition, and to 
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examine the utility of a naturalistic task of executive functioning (the Breakfast Task) in 
predicting disability. Overall, the results suggest that the prevalence of cognitive 
normality is a byproduct of the definition used. They point towards some functional 
validity of classifying above-average range, non-decrement patients as cognitively 
normal, and they also suggest that the Breakfast Task may be a promising tool to improve 
our understanding and assessment of disability.   
Approaches to Defining Cognitive Normality 
Three different definitions of cognitive normality were applied to two samples of 
patients with schizophrenia and controls: i) a narrow (IQ) definition (Study 1); ii) a broad 
(MCCB) definition (Study 1); and iii) a non-decrement, average-range definition (Study 
2).  Critically, the same inclusion and exclusion criteria were applied to participants in 
Studies 1 and 2. The review of prevalence rates reported in the existing literature may be 
confounded by the heterogeneity that is likely inherent in the various research studies. 
Applying definitions of cognitive normality to study samples that are relatively 
homogenous was an attempt to reduce the impact that heterogeneity of study samples 
may have on our ability to compare prevalence rates. Findings from the current study 
indicated that the reported prevalence of cognitive normality among patients ranges from 
9.3% (non-decrement, average range), to 14% (broad definition), to 48% (narrow 
definition). Therefore, even when the study samples are relatively homogenous, as in the 
current study, the wide range of prevalence rates still emerges. This finding suggests that 
the wide range of prevalence rates of cognitive normality reported in the literature (i.e., 
55% (Bryson et al., 1993) to 0% (Wilk et al., 2005)), is likely a byproduct of the 
definition of normality.  
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The conceptualization of cognitive normality differs between the three definitions 
used in the current studies. The commonality between the broad and narrow range 
definitions used in Study 1 is that they rely on population norms as an indication of 
whether or not patients perform within expected limits. The narrow (IQ) definition, while 
a commonly used measure of defining normality (Kremen et al., 2001), has been 
criticized for not capturing the true breadth of cognitive impairment expressed in 
schizophrenia (Gray, McMahon, & Gold, 2013; Vaskinn et al., 2014; Wilk et al., 2005). 
As predicted, the narrow definition of cognitive normality captured the largest proportion 
of patients, with 48% meeting the IQ criterion for normality. While these patients were 
seemingly intellectually preserved, this definition has not captured cognitive weaknesses 
that may have emerged on more broad-based and inclusive measures. That is, fewer 
patients emerged as cognitively normal when the broader MCCB criterion was applied – 
14%. Previous research using the MCCB to classify normality in schizophrenia found no 
subtest profile differences between cognitively normal patients and controls (Muharib et 
al., 2014), suggesting that our broad-based definition is more stringent than the narrow 
definition and does not fail to capture any cognitive weaknesses that may have emerged 
on individual subtests.  Therefore, when relying on population norms, the findings of the 
current study suggest that a greater level of stringency in the definition of normality is 
related to a reduced estimate of normality.   
The definition of cognitive normality used in Study 2 differed from those used in 
Study 1, as it directly indexed current cognitive performance against premorbid estimates 
based on reading scores and parental education. Notably, all three regression equations 
predicting current cognitive composite scores based on reading scores and parental 
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education were statistically significant (or approaching significance); however, these 
models accounted for only 5.9% to 18.3% of the variance in cognitive composite scores. 
Parental education and reading scores explained only 5.9% and 11.5% of the variance, 
respectively, indicating that approximately 85 – 90% of the variance remained 
unexplained. When these two predictors were combined in a regression equation, they 
accounted for 18.3% of the variance in cognitive composite scores, indicating that nearly 
80% of the variance continued to remain unexplained. This suggests that despite the 
popular use of parental education and oral reading as predictors of premorbid intellectual 
functioning, there remains a substantial amount of unexplained variance when they are 
used to predict current intellectual functioning.  Results pertaining to this approach to 
defining a cognitive function decrement should therefore be interpreted with this 
limitation in mind. Keefe et al. (2005) did not report R2 values associated with their 
regression equations, and therefore a comparison between their findings and the current 
results cannot be performed.   
 In Study 2, patients were classified as “truly” cognitively normal if they i) 
performed within the average-range based on a composite cognitive score, and ii) reached 
the expected level of cognitive functioning based on premorbid estimates. In study 2, 
9.3% of patients met these criteria. Consistent with findings by Keefe et al. (2005) and 
with conclusions drawn in a review of the literature by Harvey and Keefe (2009), when 
cognitive functioning is compared against the expected level of cognitive function, this 
leads to the greatest reduction in estimates of normality. Therefore, the current findings 
from Studies 1 and 2 are consistent with the study hypotheses pertaining to the 
prevalence rates of normality, with the lowest proportion of cognitive normality (9.3%) 
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emerging when performance was directly indexed against presumed premorbid functions. 
In conclusion, the level of stringency of the definition of cognitive normality, and 
reliance on population norms versus premorbid functions, leads to differences in 
estimates of normality.  
Functional and Clinical Validity of Cognitive Normality  
To determine whether the broad or narrow definitions of cognitive normality used 
in Study 1 provided greater functional or clinical validity, normal-range patients based on 
both classifications were compared to below-normal range patients, and controls. 
Regardless of the criterion applied (i.e., broad or narrow), cognitively normal patients 
remained functionally disadvantaged relative to cognitively normal controls. As well, 
however defined, cognitively normal patients demonstrated no advantage in functionality 
or clinical symptom severity relative to cognitively impaired patients. Overall, results 
suggested that the varying definitions of cognitive normality/impairment that rely on 
population norms do not have implications for the severity of psychotic psychopathology 
or community independence in treated outpatients. 
Given that cognitive impairment is commonly regarded as the determinant of poor 
functional outcome in schizophrenia (Bowie et al., 2006; Green et al., 2000; Keefe & 
Harvey, 2012; Kuo et al., 2018; Matza et al., 2006), it would have been reasonable to 
predict that those who are cognitively normal would have a functional advantage relative 
to those who are putatively cognitively impaired. However, according to meta-analytic 
findings by Fett et al. (2011), cognition accounts for only 6% of the variance in 
community functioning (with a correlation of .25); therefore the role of cognition in 
functional outcome may be over-emphasized. The lack of clinical advantage conferred by 
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either definition of cognitive normality is in line with previous studies that reported a lack 
of association between cognition and symptoms (Ammari et al., 2010; Dibben et al., 
2009; Nieuwenstein et al., 2001). The large body of evidence that suggests that cognition 
may be one of the best predictors of daily functioning cannot be dismissed; yet, the 
current findings suggest that normal cognition is not sufficient to achieve a level of 
community independence that is equivalent to that of healthy controls, consistent with 
previous studies where cognitively normal or above-normal patients remained 
functionally disabled relative to controls (Heinrichs et al., 2008; Leung et al., 2008a). 
Investigators may wish to focus future studies on factors that account for unexplained 
variance in community functioning (e.g., socio-environmental supports, brain network 
connectivity) (Raphael, 2006; Wojtalik, Smith, Keshavan, & Eack, 2017).  
Study 2 found that there is, in fact, of a proportion of patients with schizophrenia 
who perform in the cognitively normal range and who have not experienced a cognitive 
decrement, confirming the existence of “truly” normal patients. Among the patients with 
schizophrenia, 9.3% met these criteria, whereas 37.1% of patients performed in the 
average range, but have experienced a decrement based on presumed premorbid estimates 
(i.e., not “truly” normal patients). Results indicated that community independence did not 
differ between the AR decrement patient group and the AR non-decrement patient group. 
However, the combination of both above-AR cognition and lack of a cognitive 
decrement, a subset of patients making up 12.1% of the patient sample, conferred a 
functional advantage relative to AR patients with a cognitive decrement. This is 
consistent with Heinrichs et al.’s (2008) finding that verbally superior patients showed an 
advantage in terms of community independence relative to patients scoring below the 
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superior range. With respect to the functional advantage obtained by the above-AR non-
decrement patients, it is critical to note that these patients, as well as the AR non-
decrement patients continue to report significantly higher MSIF scores as compared to 
the AR non-decrement controls. These results indicate poorer community independence 
among “truly” normal or above normal patients compared to “truly” normal controls, 
again consistent with findings by Heinrichs et al. (2008). This study therefore 
demonstrated that despite a functional advantage that is conferred by being both 
cognitively above average and without having a history of a decrement, these patients 
ultimately remained functionally impaired relative to community controls. This finding is 
consistent with results from Study 1, and previous studies (Heinrichs et al., 2008; Leung 
et al., 2008a), where regardless of the classification of cognitive normality, patients 
remained functionally disadvantaged relative to controls.  This finding again highlights 
that future research may wish to identify factors, apart from cognition, that may be 
contributing to functional disability in schizophrenia.  
 With respect to the clinical validity of the decrement classification, results 
indicated that patients with a cognitive decrement reported greater negative symptom 
severity relative to patients who have not experienced a cognitive decrement, yet the two 
groups did not differ in terms of positive symptoms. Previous studies have reported an 
association between cognition and negative symptoms, but not positive symptoms 
(Addington, Addington, & Maticka-Tyndale, 1991; de Gracia Dominguez, Viechtbauer, 
Simons, van Os, & Krabbendam, 2009; Harvey, Koren, Reichenberg, & Bowie, 2006). 
Using a similar approach to classifying patients as cognitively normal or impaired, 
Ammari et al. (2010) reported that, much like the current findings, cognitively normal 
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patients reported a reduced severity of negative symptoms as compared to impaired 
patients. Given the cross-sectional nature of the current studies, it is not possible to 
determine the directionality of this relationship between lack of a cognitive decrement 
and negative symptom severity. However, it is noteworthy that the two definitions of 
cognitive normality (broad and narrow) in Study 1 were unrelated to symptom severity, 
whereas the notion of a cognitive decrement/ lack of decrement in Study 2 was related to 
symptoms. According to a review of the nature of negative and cognitive symptoms by 
Harvey et al. (2006), these two symptoms may be conceptually independent with separate 
yet related etiologies, which yields a correlation between them. For instance, pathological 
changes in separate brain regions due to related underlying white matter pathology may 
bring about cognitive and negative symptoms.  Therefore, the etiology underlying 
negative symptom expression could be related to the etiology underlying a cognitive 
function decrement. That is, rather than one symptom causing the other, they may both 
occur as a result of an association between their respective etiologies. This hypothesis has 
yet to be tested, but future studies may wish to examine the mechanisms underlying a 
cognitive decrement, and protective factors that may be at play in those patients who 
have not experienced a cognitive decrement.     
In addition to the functional implications of the above-AR non-decrement group 
of patients, it is important to also consider that this study has provided evidence that such 
a subgroup of patients does in fact exist. The existence of this subgroup is inconsistent 
with findings by Vaskinn et al. (2014), who reported that intellectually superior patients 
with schizophrenia were impaired on specific cognitive functions relative to healthy 
controls with similar superior intellectual abilities, suggesting they have experienced a 
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cognitive decrement. The current finding of an above-average group of patients without a 
cognitive decrement is, however, in line with other previous studies (Heinrichs et al., 
2008; MacCabe et al., 2012). The inconsistent findings between Vaskinn et al. (2014), 
who reported that superior patients have experienced a decrement, and Heinrichs et al. 
(2008) and MacCabe et al. (2012), who reported that it is possible to be intellectually 
superior without having had a decrement, have been attributed to small sample sizes and 
lack of statistical power in the latter studies (Vaskinn et al., 2014). A challenge inherent 
in this research is obtaining adequate sample sizes, given the low prevalence in the 
population of the patient group of interest (i.e., intellectually superior patients with 
schizophrenia). To elucidate the discrepancies in the literature surrounding the existence 
of this subgroup of patients, investigators may wish to recruit larger sample sizes to 
optimize statistical power. As well, the studies to date have been cross-sectional, and as 
such, conclusions regarding cognitive decrement have been based on estimates, rather 
than documentation of cognitive decline based on objective cognitive test scores.  
Evaluation of Keefe et al.’s (2005) Cognitive Function Decrement Algorithm 
Regarding the prevalence rates that emerged from Study 2, when WRAT-3 
Reading scores were used as an estimate of premorbid intellectual ability, 69.2% of 
patients with schizophrenia experienced a cognitive decrement according to their current 
cognitive performance, and 19.2% of patients performed at or above expected levels, and 
have therefore not experienced a cognitive decrement. Similar prevalence rates emerged 
when parental education was used as an estimate of premorbid ability, with 70.9% of 
patients meeting criteria for a cognitive decrement, and 16.3% of patients performing 
above expected levels. In the most comprehensive model, with both WRAT-3 Reading 
	 71 
scores and parental education set as predictors of current cognitive performance, 62.1% 
of patients experienced a cognitive decrement, whereas 21.4% have not.  
The preceding proportions differed significantly from those reported by Keefe et 
al. (2005), who had used the same method to assess for a cognitive decrement. 
Calculation of the odds ratio demonstrated that if a participant was in the Keefe et al. 
(2005) study, the odds of them being classified as having experienced a cognitive 
function decrement was 18 times higher than if they had participated in the current study. 
To understand the differences between the study findings, it is critical to consider that 
while the methods were similar, they were not identical. Specifically, Keefe’s (2005) 
cognitive battery was more comprehensive, including multiple measures from each 
cognitive domain. As well, Keefe et al. (2005) included measures of motor speed; the 
current study did not. Therefore, Keefe’s estimates of current cognitive functioning may 
be more precise than the estimates generated in the current study. An additional factor 
that differed between the two studies was inclusion criteria. Keefe et al.’s (2005) study 
included participants from both outpatient and inpatient clinics, whereas the current study 
recruited solely from outpatient clinics. This may be an important distinction between the 
two studies, as there is evidence supporting the association between hospitalization and 
cognitive decline, in a variety of hospital settings (Mathews, Arnold, & Epperson, 2014). 
Further, hospitalized patients with schizophrenia performed worse than outpatients on 
tasks of processing speed and flexibility (Laere, Tee, & Tang, 2018). It may be, therefore, 
that the inclusion of inpatients in Keefe et al.’s (2005) study resulted in lower overall 
cognitive performance, compared to the current study that included only outpatients. This 
could at least partially account for the greater number of patients meeting criteria for a 
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cognitive decrement in Keefe et al. (2005). Nonetheless, the current findings contradicted 
the conclusion drawn by Keefe et al. (2005) that cognitive normality in patients with 
schizophrenia largely represents a decline from premorbid estimates, and that nearly all 
patients with the disorder have sustained a cognitive decrement.  
An important finding pertaining to the cognitive decrement algorithm is the 
proportion of community controls that meets criteria for a decrement. The proportion of 
controls demonstrating a presumed cognitive decrement in the current study ranged from 
36.5% to 41.3%, depending on the predictors applied to the model. In Keefe et al.’s 
(2005) study, 30% to 48% of controls met criteria for a cognitive decrement, depending 
on the predictors applied. Given the nature of regression analyses, approximately half of 
the sample used to define the regression line will fall below the line, and half will fall 
above the line. However, this substantial proportion of controls who have experienced a 
decrement raises issues surrounding the validity of the cognitive decrement algorithm. 
According to typical estimates of impairment based on one standard deviation below the 
normal mean, 15% of the general population would be considered impaired, yet the 
current study and Keefe et al.’s (2005) study have identified a much larger proportion of 
controls who have had a decrement. Keefe et al. (2005) argued that among healthy 
controls, falling below the regression line is not necessarily indicative of being 
“cognitively unhealthy”, but rather simply indicates that controls are performing lower 
than would be expected according to different estimates (e.g., reading scores and parental 
education).  Critically, an inspection of Figures 1 and 2 in Study 2 reveals that controls 
that show a “decrement” do so to a lesser degree relative to patients, with many control 
data points appearing to fall within one standard deviation below expectations. Patients’ 
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data points, on the other hand, tend to fall much more than one standard deviation below 
the regression line. This begs the question: should all scores below the regression line be 
considered a decrement, or should more stringent criteria be applied? According to Keefe 
et al. (2005), the answer would likely be that any points below the regression line indicate 
a cognitive decrement for patients, but not necessarily for controls.  
Another critical limitation of the cognitive decrement algorithm is the use of the 
word “decrement”. Neither Keefe et al.’s (2005) study, nor the current study, included 
longitudinal analyses that allowed for a direct observation of a cognitive decrement. 
Rather, what the studies more accurately demonstrated is a discrepancy between 
participants’ current cognitive performance and an estimate of premorbid performance 
based on commonly used (yet not unflawed) predictors of intellectual functioning. The 
term “decrement” has been used in the current investigations for consistency with Keefe 
et al.’s (2005) approach. It is critical though that this term be used and interpreted with 
the aforementioned limitations in mind.  
The Breakfast Task 
The aim pertaining to Study 3 was to assess the utility of a naturalistic measure of 
executive functioning in predicting disability above and beyond clinical symptoms and 
cognition. As Studies 1 and 2 demonstrated, apart from patients who are both above-AR 
and have not experienced a cognitive decrement, cognitive normality did not confer a 
clinical or functional advantage relative to cognitively impaired patients. One hypothesis, 
therefore, is that performance on classic standardized cognitive tasks may not be 
generalizable to behaviour in everyday life. To assess this prediction, the Breakfast Task, 
a simulated ecologically relevant task that mimics a real-world activity that draws heavily 
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on executive functioning (i.e., cooking) was administered to patients with schizophrenia, 
in addition to commonly used measures of intellectual functioning (i.e., the WASI-II) and 
disability (i.e., the WHODAS).  
Administration of the Breakfast Task to patients and controls revealed that, 
similar to patients with ABI (Tanguay et al., 2014), patients were impaired relative to 
controls in their ability to ensure all of the foods finish cooking at the same time (Range 
Score). This suggests that patients with schizophrenia demonstrated reduced planning 
ability and working memory in their completion of this task. Performance on this task, 
specifically performance on the Range Score, increased the ability to predict disability 
(i.e., WHODAS scores) beyond that provided by standard cognitive (i.e., WASI-II) and 
symptom (i.e., BPRS) measures, with the complete model accounting for 23.3% of the 
variance in disability scores.  
There has been limited research on the incremental validity of more functionally 
relevant tasks in predicting real-world outcomes in schizophrenia above and beyond 
standard cognitive measures. Similar to the current results, performance on the COALS, a 
functional competence measure, added additional validity beyond that offered by 
symptoms, intellectual ability, and cognitive performance (McDermid Vaz et al., 2012). 
However, Heinrichs et al. (2010) observed conflicting results with a different measure of 
functional competence, the UPSA. Efforts to identify ecologically valid measures among 
patients with schizophrenia have found that tasks such as the Virtual Action Planning – 
Supermarket (Aubin, Béliveau, & Klinger, 2018), Computerized Digit Vigilance Test 
(Lin et al., 2018), and the Behavioural Assessment of Dysexecutive Syndrome  (Katz, 
Tadmor, Felzen, & Hartman-Maeir, 2007) demonstrate ecological validity among 
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patients with schizophrenia. However, according to Spooner and Pachana (2006), 
clinicians and researchers remain reluctant to move beyond traditional 
neuropsychological measures to more ecologically valid measures. Further, there are 
limitations inherent in the ecological validity of some measures, such as social cognitive 
measures, when applied to schizophrenia research (Vaskinn, Sergi, & Green, 2009). 
Recall that none of the three definitions of cognitive normality applied in the 
current studies provided promising functional outcome validity. When considering that 
cognition only accounts for 6% of the variance in functional outcome (Fett et al., 2011), 
and the increasing evidence that more functionally relevant tasks predict functioning or 
disability above and beyond standard cognitive tasks, the inclusion of tasks such as the 
Breakfast Task may be a promising approach to better assessing and predicting disability. 
Future research should focus on assessing if there is a subset of patients that performs 
within the normal range on more naturalistic measures, such as the Breakfast Task. 
Perhaps normal-range performance on a task such as this would have greater functional 
validity than classifications of normality based on classic standardized cognitive tasks.  
Limitations 
A notable limitation of the current investigation was that participants were 
assigned to the patient group according to criteria from an older version of the DSM (i.e., 
DSM-IV), as the current edition of the DSM (i.e., DSM-5) was not available at the outset 
of the studies. Despite the updates made to the new edition of the DSM, a recent study 
found that the majority of patients (99.5%) who met DSM-IV criteria for schizophrenia 
also met DSM-5 criteria (Mattila et al., 2015). Therefore, it is reasonable to conclude that 
the diagnostic criteria applied in the present investigations are currently valid based on 
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DSM-5 criteria.  In addition to updates made to the DSM, the WRAT-3 has been updated 
to the WRAT-4 since the conception of the current study. The WRAT-3 continued to be 
used in the study to maintain data homogeneity. The WRAT-4 includes updated norms, 
and to my knowledge, no studies have been conducted that assess if WRAT-3 premorbid 
ability estimates are comparable to WRAT-4 estimates. Notably, however, Keefe et al. 
(2005) used the WRAT-3 in their study. Given that one of the aims of the study was to 
replicate methods conducted by Keefe et al. (2005) to assess a cognitive decrement, the 
use of the WRAT-3 in present investigations is supported.  
With respect to inconsistences in measures, the MSIF was used as an assessment 
of daily functioning in Studies 1 and 2, whereas the WHODAS 2.0 was used in Study 3. 
Data from studies 1, 2, and 3 are from three separate grants, each with its own unique 
aims and methods. Therefore, the measures employed across the three studies are not 
identical. The MSIF was also administered as part of the measures in Study 3, yet there 
was inadequate training received by the test administrators to ensure appropriate 
reliability, and the results of the WHODAS were therefore reported instead. Further, the 
sample sizes, in particular among the cognitively normal-range (Studies 1 and 2) and 
above average-range (Study 2) patient groups were modest. This may have limited the 
statistical power of the findings and contributed to null findings (in particular with 
respect to normal-range compared to below-normal range group differences in ratings on 
the MSIF, as well as the PANSS).  
 As previously discussed, a second limitation involves the assessment of 
premorbid intellectual ability in Study 2. Given the cross-sectional, rather than 
longitudinal, nature of the study, premorbid IQ scores were not obtained directly and 
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were instead estimated using WRAT-3 Reading scores and parental education. Despite 
strong support for the use of both of these estimates (Bright et al., 2002; Bright & van der 
Linde, 2018; Kareken et al., 1995; Plomin, 1986; Resnick, 1992), the most accurate 
assessment of an intellectual decrement following the onset of schizophrenia would be 
direct observation through a longitudinal study design, where premorbid IQ was obtained 
through clinic-based testing. As well, despite the support of using participants’ levels of 
parental education as an estimate of their intellectual potential, a limitation inherent in 
this approach, in schizophrenia specifically, is that schizophrenia or related phenotypes in 
the family may, in fact, be associated with reduced parental education (Keefe et al., 
1994). Therefore, when interpreting the results of the second study, it is important to 
consider that parental education, as well as WRAT Reading scores, are simply estimates 
of premorbid intellectual ability, and that the term “discrepancy” is more appropriate than 
the term “decrement”.  
 An additional limitation was that not all data were corrected for education (e.g., 
WASI-II). Although normal-range and non-normal range patient groups did not differ 
from one another in terms of educational achievement in Studies 1 and 2, education has 
been shown to have an impact on different cognitive tasks (Brooks, Sherman, Iverson, 
Slick, & Strauss, 2011). As well, while a goal of the second study was to assess the 
replicability of Keefe et al. (2005), the current study and that by Keefe et al. (2005) did 
not use identical measures (although measures assessed similar cognitive domains), and 
inclusion criteria of the two studies differed (e.g., Keefe included inpatients and 
outpatients). Therefore, while the current investigation is one of the first to apply and 
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evaluate the definition of a cognitive decrement as proposed by Keefe et al., a direct 
comparison of the results of the two studies must be interpreted with caution.    
Conclusions 
The present investigation revisited the ongoing debate surrounding the existence 
of cognitively normal patients in schizophrenia, and the role of cognition in daily 
functioning. Collectively, the results of the current studies provided evidence that even 
though cognitive impairments are highly prevalent in schizophrenia, it is still possible to 
be schizophrenic and cognitively normal. That is, even when the most stringent criteria 
were applied, consisting of having not experienced a cognitive decrement based on 
premorbid estimates of parental education and reading scores, and performing within the 
average range across a comprehensive battery of neuropsychology assessments, a subset 
of patients meeting these criteria emerged (9.3% of patients, to be precise). As was 
expected, the less stringent the criteria for normality, the greater the proportion of 
cognitively normal patients that emerged. Critically, when all classifications of 
cognitively normal patients were compared to controls, they continued to remain 
functionally disadvantaged in terms of community independence, and they rarely differed 
from impaired patients in terms of clinical symptom severity. Therefore, there is 
insufficient evidence supporting the functional or clinical validity of any of the 
definitions of cognitive normality included in the present investigation, suggesting that 
the role of cognition in functioning has been largely over-emphasized in the literature.  
Given the prevalent and severe levels of disability in schizophrenia, the findings have 
implications for rehabilitation efforts aimed to improve daily functioning in 
schizophrenia. That is, efforts to enhance daily functioning through cognitive remediation 
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may be met with limited generalizability to real-world functioning, consistent with 
previous studies in the area (Kidd et al., 2014; Lin et al., 2014). There is an urgent need 
to identify and ultimately remediate other factors that are driving impaired functioning in 
schizophrenia.   
 Data from the present investigation support the use of more ecologically valid, 
naturalistic measures that provide the advantages of experimental control inherent to 
traditional tasks of executive function, with the varying demands of real-world situations 
that draw largely on executive functions. We have shown for the first time that the 
Breakfast Task, a cognitive rehabilitation measure, provides incremental validity above 
and beyond that provided by standard clinical and cognitive measures in predicting 
disability among patients with schizophrenia. Therefore, in addition to focusing our 
efforts on identifying other factors that may account for functional impairment in 
schizophrenia, we should continue to focus our efforts on more ecologically valid ways 
of assessing cognition in schizophrenia. As it is well-established that cognition is one of 
the primary predictors of daily functioning identified to date, we must not ignore the role 
that cognition plays, but instead explore novel ways to assess it that are more relevant to 
the daily functioning difficulties experienced by patients with schizophrenia. 	
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Appendices 
Appendix A. Study 1 Group Assignment: MCCB T scores between 43 and 57 
Methods 
A second approach to participant assignment to the Broad Normal-Range (BrNR) 
group was based on the following criteria: MCCB composite T score equal to or between 
43 and 57, with those T score parameters set in order to achieve psychometric 
equivalence with the WASI IQ score criterion for average-range performance (based on 
Wechsler Classification). If participants met criteria for both NaNR and BrNR, they were 
classified as BrNR for the purpose of subsequent statistical analysis to ensure that no 
participants were included in both cognitive subtype groups for group comparisons. 
Based on this broad measure, cognitively below-normal range was defined as an MCCB 
composite T score ranging from 20 to 42. This classification yielded 10 BrNR patients 
(11%), 0 above BrNR patients (0%), and 85 patients falling below the BrNR (89%) when 
applying these criteria to the entire sample of patients (n = 95). The classification yielded 
42 BrNR controls (54%), one above BrNR control (1%), and 35 below BrNR Controls 
(45%) when applying these criteria to the entire sample of controls (n = 78).  Recall the 
following prevalence rates were obtained when the MCCB composite score criterion was 
based on T scores equal to or between 40 and 60: 13 BrNR patients (14%), 0 above BrNR 
patients (0%), and 82 patients falling below the BrNR (86%), 52 BrNR controls (65%), 
one above BrNR control (1%), and 26 below BrNR Controls (33%). 
Given the low prevalence (11%) of BrNR patients (MCCB T scores between 43 
and 57), and to ensure demographic similarity with comparison subgroups, these patients’ 
age range and sex proportion were used as criteria in assigning controls to a normal range 
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(NR) ability group, patients to the NaNR ability group, and patients to the below-normal 
range group for statistical analyses. Hence, inclusion criteria for the normal range control 
group were: 1) age 20 – 46; 2) sex ratio 65-85% male; and 3) MCCB composite T score 
between 43 and 57 or IQ between 90 – 109. There were only three controls within the 
NaNR group who met age-range criteria, as the majority of controls also met criteria for 
the BrNR group. Therefore, NaNR and BrNR controls were combined to form one 
normal-range control group, rather than separating controls into their NaNR and BrNR 
groups for analyses. A total of n = 22 controls met these criteria and were assigned to a 
normal-range (NR) group. For patients, inclusion criteria for the NaNR group were: 1) 
age 20 – 46; 2) sex ratio 65-85% males; and 3) WASI Two-Subtest IQ score equal to or 
between 90 and 109. These requirements were met by n = 25 patients who were therefore 
assigned to the NaNR category. The cognitively below-normal range (BNR) patient 
group was defined as an MCCB composite score less than or equal to 42 and an IQ score 
less than or equal to 89. Applying the age, sex, IQ, and MCCB criterion to the pool of 
patients yielded n = 13 patients falling into the BNR group (see Table 11).  
Results  
 Demographic characteristics of the NaNR, BrNR patient groups (MCCB T scores 
between 43 and 57), the BNR patients, and the NR comparison controls are presented in 
Table 11. Patient and control subgroups did not differ significantly in terms of age, sex 
distribution, or proportion for whom English was their first language. Groups did differ in 
terms of years of education; the NR controls reported significantly higher levels of 
education compared to the three patient groups (ps < .05), however patient groups did not 
differ from one another in terms of years of education.    
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Table 11 
Descriptive and Criterion Data for Below Normal Range (BNR) Patients, Narrow 
Normal Range (NaNR) Patients, Broad Normal Range (BrNR) Patients, and Normal 
Range (NR) Controls, with MCCB BrNR Criteria Set at 43 > T < 57  
 
Variable BNR 
Patients 
(n = 13) 
NaNR 
Patients  
(n = 25) 
BrNR 
Patients  
(n = 10) 
NR Controls 
(n = 22) 
Statistic 
Age, yrs  
(M, SD) 
 
35.31 (6.46) 34.96 (6.54) 31.60 (7.66) 30.91 (8.77) F(3,66) = 
1.65 
Sex  
(males %) 
 
85 76 70 68 FET = 1.39 
Years 
Education 
(M, SD) 
 
11.69 (1.25) 13.08 (2.64) 13.90 (2.08) 16.45 (2.43) F(3,) = 
14.06 ** 
First 
Language 
English (%) 
 
83 84 80 52 FET = 6.30 
MCCB 
Composite T 
(M, SD) 
 
20.62 (8.64) 30.04 (7.17) 50.00 (3.39) 47.00 (6.96) F(3,65)= 
58.12 ** 
WASI 2-
Subtest IQ 
(M, SD) 
78.22 (7.42) 99.44 (5.28) 119.20 
(6.51) 
107.00 
(18.84) 
F(3,66) = 
26.15** 
Note: FET = Fisher’s Exact Test; M = mean; MCCB = MATRICS Consensus Cognitive 
Battery; SD = standard deviation; WASI = Wechsler Abbreviated Intelligence Scale.  	
Functional Implications of NaNR and BrNR Subtypes (MCCB T Scores Between 43 
and 57) 
Assumptions for ANOVA were assessed. Based on the interquartile range and 
boxplot, there were no outliers among MSIF scores. Results of the Shapiro-Wilk test (p = 
.01) indicate that the distribution of the residuals of MSIF scores was not normal, and 
residuals remained non-normally distributed following log transformation. Therefore, the 
non-parametric Kruskal-Wallis test was performed to compare the effect of group (i.e., 
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BNR patients, NaNR patients, BrNR patients, and NR Controls) on community outcome 
(i.e., MSIF global scores), with post-hoc Mann-Whitney tests conducted with Bonferroni 
correction.  
MSIF scores were significantly affected by participant group (H(3) = 34.94, p < 
.001). Mann-Whitney tests were used to follow up on this finding based on the following 
comparisons: i) BNR patients vs. NaNR patients; ii) BNR patients vs. BrNR patients; iii) 
NaNR patients vs. NR controls; and iv) BrNR patients vs. NR controls, with only these 
select Mann-Whitney tests chosen to reduce the Type I error rate while addressing the 
primary study aims, and a Bonferroni correction applied with effects reported at a .0125 
(.05/4) level of significance. Effect size values were calculated as follows: r = Z/√n, with 
r values above 0.1 representing a small effect size, values above 0.3 representing a 
medium effect size, and values above 0.5 representing a large effect size.  
Results indicated that MSIF scores did not differ between the BNR patient group 
and both the NaNR patient group (U = 128.50, p > .05, r = -.097), and the BrNR patient 
group (U = 50.50 p > .05, r = -.138). When comparing the patients with the controls, 
results indicate that MSIF global scores were significantly higher among the NaNR 
patient group as compared to the NR control group (U = 36.5, p < .01, r = -.76), and 
MSIF scores were also significantly higher among the BrNR patient group as compared 
to the NR control group (U = 14.50, p < .01, r = -.71) (see Table 12). 
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Table 12 
Community Independence and Clinical Data for Below Normal Range (BNR) Patients, 
Narrow Normal Range (NaNR) Patients, Broad Normal Range (BrNR) Patients, and 
Normal Range (NR) Controls, with MCCB BrNR Criteria Set at 43 > T < 57 
 
Variable 1. BNR 
Patients 
(n = 13) 
2. NaNR 
Patients  
(n = 25) 
3. BrNR 
Patients  
(n = 10) 
4. NR 
Controls 
(n = 22) 
Statistic Post hoc 
Comparisons 
MSIF 
Global 
Scores, 
(M, SD) 
 
4.17 
(1.40) 
3.88 
(1.04) 
3.80 
(1.03) 
1.77 (0.75) H(3) = 
34.94 
** 
2, 3 > 4 
1 = 2 = 3 
PANSS 
Positive T 
(M, SD) 
 
47.46 
(9.12) 
46.36 
(8.22) 
44.90 
(8.52) 
n/a λ = .93 n/a 
PANSS 
Negative T 
(M, SD) 
 
44.31 
(10.16) 
40.04 
(6.96) 
39.10 
(9.77) 
n/a λ = .93 n/a 
Note: MSIF = Multidimensional Scale of Independent Functioning; PANSS = Positive 
and Negative Syndrome Scale.  
** p < .001 	
Clinical implications of NaNR and BrNR Subtypes (MCCB T Scores Between 43 
and 57) 
Assumptions for MANOVA were assessed. All observations were statistically 
independent, and data were randomly sampled from the population. Based on 
Mahalanobis distance (df = 2, cut off = 13.82), there were no multivariate outliers among 
the residuals (all values were less than 8.250). Multivariate normality was assessed in R 
Studio using Mardia’s multivariate test of normality. Based on the residuals of PANSS 
Positive and Negative T scores, the Skewness (Mardia’s = 5.22, p = .27) and Kurtosis 
(Mardia’s = -.96, p = .34) indicate multivariate normality. Box’s test of equality of 
covariance matrices was not violated (M = 12.81, F(6, 9106.633) = 1.97, p = .066).  
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The MANOVA, with patient group (i.e., BNR, NaNR, and BrNR) set as the 
independent variable, and the PANSS Positive and Negative T scores set as dependent 
variables, did not show a significant difference between patient groups in terms of 
symptom severity (λ = .93, F(4, 88) = .934, ηP2 = .034, p = .548).  Therefore, BNR, NaNR 
and BrNR patient groups did not differ in terms of their positive and negative symptom 
severity (Table 12).  
Summary 
Using the MCCB criterion of T scores between 43 and 57 to classify patients as 
BrNR, 11% of patients were identified, in contrast to 14% of patients when MCCB 
criterion was based on T scores between 40 and 60. Functional and clinical implications 
of the BrNR criterion of MCCB T scores between 43 and 57 are consistent with findings 
pertaining to BrNR criterion of MCCB T scores between 40 and 60. That is, regardless of 
the MCCB criterion applied, BrNR patients were functionally disadvantaged, based on 
MSIF scores, relative to cognitively normal controls. They demonstrated no advantage in 
functionality or clinical symptom severity, based on PANSS symptom scores, relative to 
cognitively impaired patients 
 
